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Summary 
 
The human Disrupted In Renal Carcinoma 2 (DIRC2) protein consists of 478 
amino acids and is a putative member of the major facilitator superfamily.  Bioinformatic 
analysis suggested that DIRC2 has twelve transmembrane spanning domains. Both ends of 
DIRC2 are facing the cytosolic milieu. By immunofluorescence and subcellular 
fractionation analysis, it could be shown that DIRC2 localizes to lysosomes.  
The sequence of DIRC2 exhibits a dileucine lysosomal targeting motif of the 
[DE]XXXL[LI] type and two tyrosine-based lysosomal targeting sequences of the YXXØ 
type at its N- and C-terminus, respectively. Mutation of these lysosomal sorting motifs 
followed by analysis of the mutants by immunofluorescence showed that the dileucine 
motif at the N-terminus is indispensable for lysosomal targeting, whereas the two tyrosine-
based lysosomal targeting motifs are irrelevant to lysosomal targeting of DIRC2. Linear 
sequence analysis of DIRC2 also revealed two potential N-glycosylation sites. By using a 
N209A mutant and PNGase F digestion, it could be demonstrated that only Asn-209 in 
loop5 is utilized.  
Immunoblot detection of either overexpressed or endogenous DIRC2 in HeLa cells 
showed that DIRC2 is processed into two asymmetric fragments. Proteolysis of DIRC2 
takes place in lysosomes and can be prevented by ER retention or redirection of newly 
synthesized DIRC2 to the plasma membrane. The present study also showed that 
processing of DIRC2 depends on the activity of the lysosomal protease cathepsin L. 
However, DIRC2 is only partially processed in mouse liver deficient in cathepsin L, 
indicating that the role of cathepsin L in the proteolysis of DIRC2 in cathepsin L deficient 
mouse liver may be compensated by other still unknown proteases. The exact cleavage site 
of DIRC2 by cathepsin L still needs to be determined but the proteolysis is likely to take 
place between residue 214 and 261.  
Downregulation of DIRC2 with siRNAs in HeLa cells did not detectably influence 
lysosomal functions, as assessed by the activity of lysosomal enzymes or the expression 
level of lysosomal proteins. While the function of DIRC2 is currently unknown, the need 
for (or the consequence of) DIRC2 proteolysis remains unclear. Since under steady state 
xi 
 
condition the bulk of both overexpressed and endogenous DIRC2 are observed in 
processed form, it seems unlikely that the observed proteolysis corresponds to degradation. 
Hence, the possibility that the proteolytic processing modulates the function of DIRC2 
cannot be excluded. Initial functional analysis of the full length form of DIRC2, expressed 
in Xenopus oocytes, indicated that DIRC2 is an electrogenic transporter protein. However 
the actual substrate of DIRC2-mediated transport is still unknown. 
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Zusammenfassung 
 
Das humane Protein Disrupted In Renal Carcinoma 2 (DIRC2) besteht aus 478 
Aminosäuren und ist ein vermeintliches Mitglied der Major-Facilitator-Superfamilie. 
Bioinformatische Analysen lassen vermuten, dass DIRC2 ein zwölf 
Transmembrandomänen umfassendes Protein ist, dessen Enden beide im Cytosol liegen. 
Mit Hilfe von Immunfluoreszenzexperimenten und subzellulärer Fraktionierung konnte 
gezeigt werden, dass DIRC2 eine lysosomale Lokalisation besitzt. 
DIRC2 weist drei lysosomale Zielsequenzen auf. Neben einem Dileucinmotiv des 
[DE]XXXL[LI]-Typs sind zwei tyrosinbasierte YXXØ-Sequenzen jeweils am N- und C-
Terminus enthalten. Mutationen innerhalb dieser Sortierungsmotive, gefolgt von 
anschließender immunfluoreszenzbasierter Analyse, zeigten die Notwendigkeit des N-
terminalen Dileucinmotifs, nicht aber der YXXØ-Motive für den zielgerichteten Transport 
von DIRC2 zu den Lysosomen. Weitere Sequenzanalysen von DIRC2 ergaben  zwei 
potentielle N-Glykosylierungsstellen.  Unter Verwendung einer DIRC2-N209A Mutante 
und deren Deglykosylierung mittels PNGase F konnte gezeigt werden, dass nur dieses 
Asn-209 glykosyliert vorliegt. 
Immunoblotanalysen des überexprimierten oder endogenen DIRC2 in HeLa-Zellen 
zeigten, dass eine Prozessierung des Proteins in zwei asymmetrische Fragmente erfolgt. 
Die Proteolyse von neusynthetisiertem DIRC2 findet in den Lysosomen statt und kann 
durch eine ER-Retention oder einen umgeleiteten Transport zur Plasmamembran 
verhindert werden. Die Untersuchung zeigte außerdem, dass die DIRC2-Prozessierung von 
der lysosomalen Protease Cathepsin L abhängt.  Eine jedoch weiterhin stattfindende 
partielle DIRC2-Prozessierung in Lebern Cathepsin L-defizienter Mäuse könnte auf eine 
Kompensation von Cathepsin L durch andere, noch nicht identifizierte Proteasen 
hindeuten. Die genaue Cathepsin L-Schnittstelle im DIRC2 Protein muss zwar noch 
aufgeklärt werden, konnte aber auf einen Bereich zwischen den Aminosäureresten 214 und 
261 eingegrenzt werden. 
Durch eine siRNA-induzierte Verhinderung der DIRC2-Expression in HeLa-Zellen 
konnte kein messbarer Effekt auf die Aktivität lysosomaler Enzyme, sowie die 
xiii 
 
Expressionsspiegel lysosomaler Proteine festgestellt werden. Die genaue Funktion von 
DIRC2 bleibt also weiterhin unklar und somit auch die Notwendigkeit (oder die 
Konsequenz) der Proteolyse von DIRC2. Jedoch scheint es unwahrscheinlich, dass die 
Proteolyse nur auf den Abbau von DIRC2 zurückzuführen ist, da unter steady state- 
Bedingungen der Hauptanteil, sowohl des überexprimierten, als auch des endogenen 
DIRC2 in prozessierter Form vorliegt. Demnach kann eine Modulierung der Funktion, 
durch proteolytische Prozessierung nicht ausgeschlossen werden. Kürzlich begonnene, 
funktionell Analysen des unprozessierten, in Xenopus oocyten exprimierten DIRC2, 
deuteten darauf hin, dass es sich bei dem Protein um ein elektrogenes Transporterprotein 
handeln könnte. Allerdings sind dessen mutmaßliche Substrate bis jetzt unbekannt. 
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1. Introduction 
1.1 Lysosomes 
Lysosomes are acidic membrane-bound cytoplasmic organelles that serve as a major 
degradative compartment in eukaryotic cells. They were first described by de Duve over 50 
years ago (de Duve 1955, de Duve 1959), and were also termed “suicide bags”, referring to 
their potential function as subcellular particles responsible for protein turnover. Until the 
discovery of the ubiquitin-proteasome system, lysosomes were thought to be the sole major 
players in intracellular protein degradation or turnover (Chiechanover 2005). The discovery of 
the ubiquitin-proteasome system has indeed changed the knowledge in the field of protein 
degradation. However, this advance did not marginalize the study of lysosomes, because it 
turned out that varieties of biomacromolecules, such as glycoconjugates, lipids, and nucleic 
acids, are also degraded within the lysosome, followed by the releasing their building blocks 
and transporting the catabolic products back to the cytoplasm for reuse (Cuervo and Dice 
1998).  
Both endogenous and exogenous macromolecules can be delivered to lysosomes 
through the biosynthetic, autophagic, and endocytic pathway, respectively (Figure 1.1). The 
degradative function of these organelles is carried out by around 50 acid hydrolases within 
their lumen, such as proteinases, lipases and glycosidases.  The acidic nature of lysosomes is 
due to the activity of the vacuolar H
+
-type ATP-ase which pumps protons into the lysosomal 
lumen and thereby maintains the pH at 4.5-5 (Mellman et al 1986). Lysosomes also serve as 
the destination for cytoplasmic constituents taken up via autophagy which are targeted for 
degradation and recycling. Lysosomes also have a role in the downregulation of cell surface 
receptors, inactivation of pathogenic organisms, repair of the plasma membrane after 
wounding, and loading of processed antigens onto MHC class II molecules (Storch and 
Braulke 2005).  
 
1.2 Targeting of Lysosomal Proteins 
The correct localization of both soluble lysosomal proteins and membrane proteins 
results from highly regulated sequential events. The best characterized lysosomal targeting 
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pathway for soluble lysosomal proteins is the mannose-6-phosphate receptor pathway. 
Additionally, there is also a mannose-6-phosphate receptor independent pathway. For 
lysosomal membrane proteins, certain motifs owned by these proteins have been known to be 
decisive for their lysosomal fate (reviewed by Braulke and Bonifacino 2009, Saftig and 
Klumperman 2009). 
Figure 1.1. Schematic description of lysosomal system (modified from Ciechanover 2005).       
Exogenous proteins are targeted to the lysosome through receptor-mediated endocytosis and pinocytosis. 
Exogenous particles or bacteria are targeted by phagocytosis. Endogenous proteins and cellular organelles are 
targeted by microaoutophagy and macroautophagy, respectively.               
 
The majority of lysosomal hydrolases are tagged by mannose-6-phosphate during 
transport through the Golgi complex (Sleat et al 2005), which are later recognized by 
mannose-6-phosphate receptors (MPRs) in the trans-golgi network (TGN) (Kornfeld and 
Mellman 1989, von Figura and Hasilik 1986). These ubiquitiously expressed receptors could 
either be the cation-dependent MPR of 46 kD (MPR46 or CD-MPR) or the cation-
independent MPR of 300 kD (MPR300 or CI-MPR) (Gosh et al 2003, Braulke and 
Bonifacino 2009). The MPR-ligand complexes form a membranic intermediate with clathrin. 
The later complex exits the TGN and fuses with early endosomes. In this mildly acidic 
compartment (pH 6), the MPR-ligand is dissociated to release the cargo, and the MPR is 
                                                                                                                                                              Introduction 
3 
 
transported back to the TGN for further cycles of transport (Figure 1.2). The acid hydrolases 
follow subsequent maturation steps of early endosomes, which involve several fusion evens, 
and are finally contained in mature lysosomes (Figure 1.2). A minor amount of MPRs (up to 
10%), exclusively of the CI-MPR/MPR300 type,  are also found at the plasma membrane and 
reported to be involved in the endocytosis of exogenous ligands (Braulke et al 1987, Breuer et 
al 1997, Braulke and Bonifacino 2009). 
 
Figure 1.2 Targeting of lysosomal proteins (taken from Braulke and Bonifacino 2009). 
All mannose-6-phosphate modified hydrolases bind to mannose-6-phosphate receptor or to sortilin in the TGN, 
whereas beta-glucocerebrosidase binds to LIMP-2. The enzyme-receptor complex concentrates in the 
clathrin/GGA/AP-1-coated areas of the TGN followed by transport to endosomes. In this acidic compartment, 
hydrolases are released from their receptors and follow subsequent maturation steps. MPR and sortilin are 
transported back to the TGN by a set of retrograde transport machinery, which includes retromer and TIP47, 
whereas LIMP-2 resides in the limiting membrane of lysosomes. MPR and other receptor may also act as a 
receptor for extracellular proteins. TGN, trans-Golgi network; βGC, beta-glucocerebrosidase; LIMP-2, lysosome 
integral membrane protein 2; MVB, multivesicular body; GGA, golgi-localized -ear containing adenosine 
diphosphate ribosylation factor-binding protein; AP, adaptor protein; TIP47, tail interacting protein of 47 kDa. 
LIMP-2 
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Study of patients with I-cells disease (mucolipidosis type II) demonstrated that they, 
despite the lack of mannose-6-phosphate tagged lysosomal hydrolases due to defective 
GlcNAc-1-phosphotransferase, do have normal lysosomal enzyme levels in many organs 
(Waheed et al 1982, Kornfeld and Sly 2001). Further studies on either GlcNAc-1-
phosphotransferase-knockout mice (Gelfman et al 2007) or mice deficient for both type sof 
MPR46 and MPR300 (Dittmer et al 1999) have also revealed similar observations. This led to 
the unravelling of the existence of MPR-independent route(s) for the transport of lysosomal 
hydrolases. To date, however, very limited information is known about the MPR-independent 
pathway. Among these alternative receptor proteins sortilin has been described to mediate 
lysosomal trafficking of prosaposin and acid sphingomyelinase (Lefrancois et al 2003, Ni and 
Morales 2006), and more recently the lysosomal integral membrane protein type 2 (LIMP-2) 
has been identified as a specific receptor for lysosomal transport of -glucocerebrosidase 
(GC, Figure 1.2) (Reczek et al 2007). 
In contrast to most soluble lysosomal proteins, lysosomal membrane proteins are not 
modified with mannose-6-phosphate and their transport from TGN to the lysosome is mostly 
independent of MPRs. The transport of lysosomal membrane proteins is achieved either by 
direct intracellular route or by indirect route through plasma membrane followed by 
subsequent endocytic evens (Janvier and Bonifacino 2005). The signals for lysosomal 
targeting of lysosomal membrane proteins are mostly contained in their cytosolic tails 
(Bonifacino and Traub 2003). The best characterized lysosomal targeting signals for 
lysosomal membrane proteins are the tyrosine motif YXXØ (Peters et al 1990, Williams and 
Fukuda 1990) and the dileucine motif DEXXXLLI, where X represents any amino acid 
and Ø represents hydrophobic amino acid (Letourneur and Klausner 1992). Additionally, it 
has also been known that the mannose-6-phosphate receptor proteins have their own sorting 
signals (Gosh 2003). This signal consists of a cluster of acidic residues followed by a 
dileucine motif (DDSDEDLL in the MPR300 and EESEERDDHLL in the MPR46, or simply 
DXXLL motif) (Braulke and Bonifacino 2009). Some examples of lysosomal membrane 
proteins with their respective lysosomal targeting signals are listed in Table 1.1. The role of 
LIMP-2 as a receptor for GC and the fact that this protein itself is a lysosomal membrane 
protein, which is not recycled back to the TGN after releasing of GC, has shown that the 
lysosomal targeting pathways of membrane protein and soluble lysosomal protein can overlap 
(Saftig and Klumperman 2009). 
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DXXLL signals are also known as the minimal motif, since alteration of either aspartic 
acid or any of the two leucines to small amino acid such alanine leads to inactivation of the 
signals and causes mis-targeting of protein to the cells surface membrane. Most DXXLL 
signals are located nearly at the end of carboxy termini of cytosolic tail of lysosomal 
membrane proteins. DXXLL signals are recruited by the mammalian GGAs through their 
VHS domain (domain present in Vps27p, Hrs, Stam protein; Bonifacino and Traub 2003). 
GGAs belong to the family of ADP-ribosylation factor (ARF)-dependent clathrin adaptors 
localized to the TGN and endosomes (Figure 1.2;  Bonifacino and Traub 2003). It has also 
noticed that the interaction between GGAs and DXXLL is highly specific, as VHS domains 
from other proteins, such as Hrs, STAM1, TOM1 and TOM1L1 do not bind DXXLL signals. 
Accordingly, the VHS domains of the GGAs recruit neither DEXXXLLI nor YXXØ 
signals (Bonifacino and Traub 2003). 
 
DEXXXLLI  Signals are very important in sorting of many of type I, type II and 
multispanning transmembrane proteins (Table 1.1). As in the case of DXXLL signals, the 
DEXXXLLI  signals commonly have acidic cluster preceding the dileucine motif. In 
addition, the first leucine of this signal is not interchangeable with isoleucine without loss of 
activity, whereas substitution of the second leucine with isoleucine retains signal activity 
(Letourneur and Klausner 1992).  In contrast to the DXXLL signals, the DEXXXLLI  
signals of late endosomal or lysosomal proteins are commonly located close to 
transmembrane domains (typically 6-11 residues apart). Additionally, these signals can be 
either at the carboxy termini (e.g. NPC1, LIMP-2) or at the amino termini (e.g. Ii) (Bonifacino 
and Traub 2003). These signals are recruited by adaptor proteins (APs) which later form 
complex with clathrin (Figure 1.2). 
 
Also known as tyrosine-based sorting signals, the YXXØ motifs interact with the  
subunits of adaptor protein which later form complexes with clathrin. These signals also 
require that they are located close to transmembrane domains (6-11 residues) to be effectively 
recruited by the adaptor proteins. 
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Table 1.1 Examples of dileucine-based and tyrosine-based sorting signals  
(adapted from Braulke and Bonifacino 2009). 
 
Protein Motif Sequence 
Type DXXLL 
MPR300/Cl-MPR SFHDDSDEDLL 
MPR46/CD-MPR EESEERDDHLL 
Sortilin GYHDDSDEDLL 
 SorLA/SORL1 ITGFSDDVPMV 
 GGA1 (1) ASVSLLDDELM 
 GGA1 (2) ASSGLDDLDLL 
 GGA2 VQNPSADRNLL 
 GGA3 NALSWLDEELL 
 
  
Type DEXXXLLI 
LIMP-2 DEGTADERAPLI 
 NPC1 EERYKGTERERLL 
 Mucolipin-1 PAGPRGSETERLL 
 
 
Sialin DGEESTDRTPLL 
 GLUT8 PEDPEETQPLL 
Invariant chain (Ii) EDQKPVMDDQRDL
I 
 
  
 
Type YXXØ 
LAMP-1 GYQTI 
 LAMP-2A GYEQF 
 LAMP-2B GYQTL 
 LAMP-2C GYQSV 
 CD63 GYEVM 
 CD68 AYQAL 
Endolyn AYQAL 
 DC-LAMP GYQRI 
 Cystinosin GYDQL 
 Sugar phosphate exchanger 2 GYKEI 
 Acid phosphatase GYRHV  
 
 
1.3 Soluble Lysosomal Proteins 
Degradative function of lysosomes are carried out by hydrolytic enzymes which are, 
according to their substrates, classified as proteases, glycosidases, lipases, nucleases, 
phosphatases and sulfatases (Journet et al 2002, Kollmann et al 2005, Sleat et al 2005). 
Lysosomal proteases include three subgroups which represent their active site amino acids: 
cysteine, aspartic and serine proteases (Brix 2005, Siintola 2008). Although they are 
contained within the lumen of lysosomes and protected by the lysosomal membrane, the 
proteases are usually detected within all vesicles of the endocytic pathway, i.e. early 
endosomes, late endosomes, autophagic vacuoles, and lysosomes. Several lysosomal 
proteases such as the aspartic proteinase cathepsin D or cysteine proteases cathepsin B, H and 
L, were reported to be ubiquitiously expressed, while others tend to be tissue-specific (Brix 
2005). 
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Among lysosomal proteases, lysosomal cysteine proteases have long been subject of 
many studies. Lysosomal cysteine proteases, also known as cathepsins, are optimally active in 
the acidic and reducing condition found in lysosomes. Nevertheless, recent studies emphasize 
that cathepsins are not only active in the acidic milieu of endosomes/lysosomes. A nuclear 
isoform of cathepsin B has been reported to be involved in the development of thyroid 
malignancies (Tedelind et al 2010). Similarly, a cathepsin L isoform devoid of a signal 
peptide has also been reported to be localized in the mammalian cell nucleus (Goulet et al 
2004). Cathepsin cysteine proteases share similar amino acid sequences and folds, and 
comprise a group of papain-related enzymes (Turk 2001).  
 
Table 1.2 Human lysosomal cysteine proteases: Nomenclature and properties (taken from Turk et al 2001). 
Name Synonyms Endopeptidase Exopeptidase  Chromosome 
localization Carboxypeptidase Aminopeptidase 
cathepsin L - + - - 9q21 
cathepsin V cathepsin L2 + - - 9q21 
 cathepsin U     
cathepsin S - + - - 1q21 
cathepsin K  cathepsin O + - - 1q21 
 cathepsin O2     
 cathepsin X     
cathepsin W Lymphopain n.d. n.d. n.d. 11q13 
cathepsin F - + - - 11q13 
cathepsin O - n.d. n.d. n.d.  4q31-32 
cathepsin B cathepsin B1 + + - 8p22-23 
   dipeptidase   
cathepsin X cathepsin Z - + - 20q13 
 cathepsin P  monopeptidase   
 cathepsin Y  also dipeptidase   
cathepsin H cathepsin I + - + 15q24-25 
    monopeptidase  
cathepsin C dipeptidyl peptidase I - - +  
 cathepsin J   dipeptidase 11q14 
 
The majority of cathepsins are endopeptidases with exception of cathepsin C 
(aminopeptidase, Barret et al 1998), cathepsin X (carboxy mono- or dipeptidase, Klemencic et 
al 2000). Cathepsin B and H, which are endopeptidases, also show carboxypeptidase and 
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aminopeptidase activity, respectively (Turk et al 2001). Cathepsins are synthesized as 
proenzymes which require activation step(s). In vivo activation of procathepsins of the 
endopeptidase subgroup can be achieved by autoactivation in acidic environment or by 
glycosaminoglycans (Turk et al 2000). In contrast, the true exopeptidases, cathepsin X and 
cathepsin C, need to be activated by the activity of endopeptidases, such as cathepsin L and S 
(Nägler et al 1999, Dahl et al 2001, Turk et al 2001). Table 1.2 summarizes the nomenclature 
and properties of lysosomal cathepsins. 
An example of a well described cathepsin cysteine protease is given by the cathepsin 
B. It is the first cathepsin being crystallized (Musil et al 1991, Turk 2001) and the first 
cathepsin being knocked out (Deussing et al 1998, Foghsgaard et al 2001, Brix 2005). 
However, cathepsin B knockout mice have shown no overall alteration in their phenotype 
(Deussing et al 1998), but a reduction in premature intrapancreatic trypsinogen activation, and 
increased resistance to tumor necrosis factor-alpha mediated hepatocyte apoptosis 
(Foghsgaard et al 2001, Guicciardi et al 2001). Its activity is inhibited by cysteine protease 
inhibitor such as leupeptin, cystatin B and E-64. 
Cathepsin L represents one of the most potent lysosomal cysteine protease. It is 10 to 
15 times more active than cathepsin B (Gordon et al 1995). It is involved in the processing of 
the spike (S) protein of  severe acute respiratory syndrome coronavirus (SARS-CoV) (Bosch 
et al 2008) and in the  perforin processing (Konjar et al 2010). However, as in the case of 
cathepsin B, cathepsin L deficient mice show only a mild phenotype, i.e. a reduction in CD
+
 T 
cells (Nakagawa et al 1998) and recurrent hair loss (Roth et al 2000) and in the turnover of 
autophagolysosomes (Dennemaerker et al 2010). This suggests that lysosomal cysteine 
proteases are likely to be redundant (Nagler and Menard 2003, Brix 2005). On the other hand, 
a severe phenotype was reported in cathepsin B and L double deficient mice, which showed 
an early-onset brain atrophy which led to the death of animal four weeks after birth (Felbor 
2002).  
The above description of cathepsins, represented by cathepsin B and L, highlights the 
challenges in the understanding of the specific roles and natural substrates of individual 
lysosomal proteases. 
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1.4 Lysosomal Membrane Proteins 
The limiting membrane of lysosomes contains a set of highly glycosylated lysosomal-
associated membrane proteins (LAMPs) such as LAMP-1 and LAMP-2, and lysosomal 
integral membrane proteins such as LIMP-1 (CD63/LAMP-3) and LIMP-2. The limiting 
membrane has multiple functions including acidification of the lysosomal matrix, 
sequestration of the lysosomal enzymes from the rest of the cytoplasm, mediation of fusion 
events between lysosomes and other organelles, and transport of degradation products back to 
the cytosol (Eskelinen et al 2003).  
Lysosomes were initially thought to be non-specifically permeable to small molecules, 
allowing the degraded materials within the lysosomes to be transported out of lysosomes for 
further use. This view was changed after the identification of protein-mediated pathway for 
cystine across the lysosome membrane (Gahl et al 1982, Jonas et al 1982). Further studies 
have also revealed the existence of transport pathways for amino acids, di- or tripeptides, 
sugars, inorganic ions and nutrients in purified lysosomal fractions (Pisoni and Thoene 1991, 
reviewed by Sagné and Gasnier 2008). Thereafter, many studies have been carried out to 
unravel the composition and the dynamic of lysosomal membrane. 
 
1.4.1 Proteomic study of lysosomal membrane proteins 
The study of lysosomal membrane proteins relies mostly on the availability of a highly 
pure lysosomal fraction. A comprehensive study of lysosomal membrane composition has 
been performed by Bagshaw and colleagues (Bagshaw et al 2005). This study has taken 
advantage of shifting the buoyant density of rat lysosomes by treating the rat with Triton 
WR1339, which provides a comfortable fractionation step in a sucrose gradient.  In this way, 
the Triton WR1339-filled lysosomes (Tritosomes) retain their lysosomal enzymes activities, 
as well as their ability to fuse with endosomes/phagosomes. The subsequent tandem MS 
analysis of the fraction enriched in lysosomes has revealed over 200 proteins, with many of 
which were previously associated with lysosomes/endosomes (Bagshaw et al 2005). 
However, copurification of endoplasmic reticulum, golgi, cytosol, plasma membrane and lipid 
raft proteins in the lysosome enriched fraction could not be avoided. 
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Subsequent advance in the proteomics study of lysosomal membrane protein has been 
reported by Schroeder et al (Schroeder et al 2007). In this study, lysosomal membrane 
proteins were isolated from human placenta and statistical analysis was introduced to 
significantly exclude co-purified proteins. A lysosome enriched fraction was initially 
produced by percoll gradient centrifugation, followed by selective disruption of lysosomes of 
the lysosome enriched fraction by applying osmotic stress during incubation with methionine 
methyl ester. The co-purified mitochondria and lipofuscin were then removed in the sucrose 
and iodixanol gradient centrifugation, consecutively. LC-MS/MS data of the lysosomal 
membrane enriched fraction were compared to the data from material after the first density 
gradient centrifugation. By using this strategy, Schroeder et al were able to exclude the 
majority of known mitochondrial, ER, plasma membrane and peroxisomal membrane 
proteins. 58 proteins previously known to reside at least partially in lysosomes were 
confirmed, and additional 86 proteins were significantly enriched in the lysosomal membrane 
fraction, 12 of which were novel proteins with unknown function (Schroeder et al 2007, 
reviewed in Lübke et al 2009). 
 
1.4.2 Lysosomal transporter proteins 
The significance of the lysosome is underlined by the fact that around 50 diseases are 
related to lysosomal storage dysfunction. The majority of the diseases are caused by defects in 
soluble lysosomal proteins, whereas only few are related to defect in lysosomal membrane 
proteins. With the sole exception in the Mucopolysaccharidosis IIIC disorder (MPS IIIC, or 
Sanfilippo C syndrome, Hrebicek et al 2006), all of the known diseases related to the defect in 
the lysosomal membrane proteins are caused by defects in non-enzymatic membrane proteins, 
i.e. lysosomal transporter, channel or receptor proteins (Ruivo et al 2009). Table 1.3 lists a 
number of lysosomal transport proteins, which includes those related to lysosomal storage 
diseases. 
The first characterized lysosomal storage disorder caused by failure of the transport of 
catabolism products across lysosomal membrane is cystinosis. In this disease, Cystinosin, a 7-
transmembrane-domain transporter, is defective and result in the failure to export cystine out 
of lysosomes. Clinical pathology of this disease are found in the kidney, eye, liver, muscles, 
pancreas, brain and white blood cells and are manifested in growth retardation, diabetes 
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mellitus, hypothyroidism, myopathy and neurological deterioration (Kalatzis 2001, Ruivo et 
al 2009, Saftig and Klumperman 2009). In the Salla disease, transport of free sialic acid from 
lysosome is impaired, due to the mutation in Sialin, a 12 transmembrane-domains lysosomal 
transporter protein (Morin et al 2004, Wreden et al 2005). By the progress in the proteomics 
study of lysosomal membrane proteins, it is anticipated that more lysosomal transporters will 
be unveiled (Schroeder et al 2007, Ruivo et al 2009). 
Table 1.3 Lysosomal transport activities and proteins from the lysosomal membrane with demonstrated or 
putative transport function (modified from Sagné and Gasnier, 2008). 
Substrates transported Transport protein 
(human gene) 
Mechanism Associated 
inherited disorder 
(OMIM no) 
References 
Protein catabolites     
Lys, Arg (system c) ?   Pisoni et al (1985, 
1987b) 
Glu, Asp (system d) ?   Collarini et al (1989) 
Ala, Ser, Thr (system e) ?   Pisoni et al (1987a) 
Pro, Ala, Ser, Thr (system f) ?   Pisoni et al (1987a) 
Pro (system p) ?   Pisoni et al (1987a) 
Pro, Ala, Gly LYAAT1 (SLC36A1) H+ symport  Sagné et al (2001) 
Leu, Phe, Thr (system t) ?   Stewart et al (1989) 
Ile, Leu, Phe, Trp, Tyr 
(system h) 
?   Bernar et al (1986) 
Leu, Ile, Val, Met, Phe 
(system l) 
?   Stewart et al (1986) 
Cystine Cystinosin (CTNS) H+ symport Cystinosis (219800) Town et al (1998), 
Kalatzis et al (2001) 
Cystine, glutamate xCT Cystine/gluta-
mate antiporter 
 Sakakura et al 2007 
Cysteine*, cysteamine* ?   Pisoni et al (1990) 
Di- and tripeptides ?   Thamotharan et al 
(1997) 
His, dipeptides  PHT2 (SLC15A3) H+ symport   
    Sakata et al (2001) 
Carbohydrate catabolites     
Neutral hexoses GLUT8 (SLC2A8)? Uniport or              
H+ symport 
 Doere et al (2000), 
Ibberson et al (2000), 
Augustin et al (2005), 
Schroeder et al (2007) 
GlcNAc, GalNAc ?   Jonas et al (1989) 
Sialic acids, acidic hexoses Sialin (SLC17A5) H+ symport Salla disease (604369) 
ISSD (269920) 
Verheijen et al (1999), 
Morin et al (2004) 
Myo-inositol HMIT (SLC2A13)   Uldry et al (2001), 
Schroeder et al (2007) 
     
Inorganic ions     
H+* 
 
 
 
V-ATPase 
(ATP6Vxxx) 
ATP driven Infantile malignant 
osteopetrosis 
(ATP6VA3, 259700) 
Forgac (2007) 
PO4- ?   Pisoni (1991) 
SO4- SLC26A11?   Jonas and Jobe (1990), 
Schroeder et al (2007) 
Ca2+ ?   Lemons and Thoene 
(1991) 
Ag2+, Cu2+, Cd2+ ?   Havelaar et al (1998) 
Monovalent cations Mucolipin 
(MCOLN1) 
Channel Mucolipidosis type IV 
(252650) 
Bach (2005) 
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Fe2+ and other divalent 
metal ions 
DMT1 (SLC11A2), 
IRE + splicing 
isoform 
H+ symport  Gunshin et al (1997), 
Tabuchi et al (2002) 
K+, Cl- KCC1 (SLC12A4) K+, Cl- symport  Schroeder et al (2007) 
Zn2+* ZnT2 (SLC30A2)   Palmiter et al (1996), 
Schroeder et al (2007) 
Cl- CLC-7 (CLCN7) + 
Ostm1 (OSTM1) 
H,, Cl- 
antiporter 
Infantile malignant 
osteopetrosis (259700) 
Kornak et at (2001), 
Lange et al (2006), 
Weinert et al (2010) 
     
Other     
Polymannose* ?   Saint-Pol et al (1997, 
1999) 
Nucleosides ENT3 (SLC29A3) Uniport or             
H+ symport 
 Baldwin et al (2005) 
     
Folylpolyglutamate ?   Barrueco and Sirotnak 
(1991), Barrueco et al 
(1992) 
Vitamin B12 LMBD1 (LMBRD1)   Rutsch et al (2009) 
6-mer peptides* TAP-like (ABCB9) ATP-driven  Wolters et al (2005) 
     
Unknown     
Arg, Lys? CLN3  Juvenil neuronal 
ceroid-lipofuscinosis 
(204200) 
Consortium (1995), 
Kim et al (2006), 
Ramirez-Montealegre 
and Pearce (2005) 
? CLN7 (MFSD8)  Late infantile neuronal 
ceroid-lipofuscinosis 
(610951) 
Bagshaw et al (2005), 
Schroeder et al (2007), 
Siintola et al (2007) 
     
     
Fatty acids? NPC1  Niemann-Pick disease 
type C1 (257220) 
Carstea et al (1997), 
but see Passeggio and 
Liscum (2005) 
? P40   Boonen et al (2006) 
? Spinster-like protein 
1 
  Bagshaw et al (2005), 
Schroeder et al (2007) 
Choline? CTL2 (SLC44A2)   Schroeder et al (2007) 
? C19orf28   Schroeder et al (2007) 
     
Asterisks (*) indicate the substrates which are imported into the lysosomes under physiological conditions. 
Transport proteins underlying these activities are indicated in the second column. Most known proteins are 
secondary active transporters indirectly driven by the lysosomal ATPase through an H
+
 coupling mechanism. 
The table also lists primary transporters which are directly coupled to ATP hydrolysis and ion channels. 
Inherited diseases resulting from mutations of the corresponding genes are indicated in the fourth column. 
 
1.4.3 Disrupted in Renal Carcinoma 2 (DIRC2) 
The DIRC2 gene was initially reported in the context of renal carcinoma as this gene 
spans the breakpoint of a chromosomal translocation observed in a few cases of familial renal 
cancer (Bodmer et al 2002). DIRC2 gene is expressed in various tissues, including kidney. 
DIRC2 encodes a predicted protein of 478 amino acids residues with a high homology to the 
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human feline leukaemia virus subgroup C receptor, FLVCR (Bodmer et al 2002). FLVCR 
involves in the transport of free heme out of cytoplasm, which is other ways toxic for the cells 
(Keel et al 2008).  DIRC2 shows also similarity to various putative transporters of major 
facilitator superfamily (MFS, section 1.5) transporter proteins. Transcript of the DIRC2 shows 
a high homology (80%) to the transcripts from different species, including monkey, pig, dog 
and mouse (Bodmer et al 2002). A significant degree of homology (30-45%) of human 
DIRC2 to different proteins from Leishmania major and Arabidopsis thaliana has also 
emphasized the conservation of this protein (Bodmer et al 2002). 
DIRC2 is predicted to have 12 transmembrane spanning domains, which is the basic 
characteristic of MFS. Additionally, it has a conserved MFS-specific signature sequence 
which lays between transmembrane domain 2 and 3 (Maiden et al 1987, Law et al 2008, 
Bodmer et al 2002). DIRC2 is one of putative lysosomal membrane proteins identified in a 
recent proteomics study of lysosomes purified from human placenta (Schroeder et al 2007). 
Bioinformatic analysis of this DIRC2 suggests that it contains one glycosylation site and 
several phosphorylation sites. Additionally, DIRC2 has a proline rich region (P-x-x-P) 
between transmembrane domain 6 and 7, which is known to be a potential interaction site 
with Src homology 3 (SH3) domains from several proteins (Rickles et al 1994, Bodmer et al 
2002). Apart from this genetic description of DIRC2, there is currently no further report about 
the biochemical and molecular aspects of DIRC2. 
 
1.5 Major Facilitator Superfamily 
Transport of biomolecules and inorganic materials across cytoplasmic and vesicular 
membranes is very important for the life of cells. The transport across membranes can be 
driven by the energy released by hydrolysis of ATP (primary transporters), or by the use of 
energy stored in the ion or solute gradients generated by primary transporters (so-called 
secondary transporters). In the group translocation system commonly found in bacteria, 
chemical modification of substrate results in transport of substrate onto the opposite side of 
membrane (Law et al 2008). The MFS proteins transport their substrate by uniport 
(translocation of a single species), symport (translocation of substrate and an ion in the same 
direction) or antiport (translocation of substrate and an ion or another substrate in opposite 
directions) (Kaback et al 2001). 
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Major facilitator superfamily (MFS) represents a group of secondary transporter 
proteins with thousands of members from all kingdoms of life and all living cells (Law et al 
2008). In prokaryotes, around 25% of all known membrane transport proteins belong to the 
MFS (Saier et al 2003). This large superfamily is subgrouped  into tenth of families on the 
base of both their functionality and phylogenic data (Saier et al 1999).With exception of only 
three families among 58 families known to date, all proteins belonging to MFS are 
characterized by twelve -helices transmembrane domains (TMDs) connected by hydrophilic 
loops, and  both their N- and C-termini reside in the cytoplasm (Pao et al 1998, Saier 2003).  
 
The difficulty to purify, crystallize and resolve the structure of MFS protein has long 
kept the gap between structural and functional study of MFS proteins. Despite the lack of 
structural evidence, a growing list of human diseases has been related to the mutation of 
transporter proteins (Kaback et al 2001). Nevertheless, the current understanding of MFS 
transporter protein was boosted by the high-resolution structures of two proteins from this 
superfamily: the lactose permease symporter (LacY; Abramson et al 2003) and the glycerol-3-
phosphate antiporter (GlpT; Huang et al 2003) from Escherichia coli. An intriguing fact of the 
two MFS proteins of different family is that they have very similar structure, although they 
share only 21% sequence identity. Significant sequence similarities are only identified among 
MFS proteins within the same family (Pao et al 1998). This leads to the hypothesis that all 
members of the MFS share a common structure (Vardy et al 2004). 
 
The above hypothesis is further strengthened after the high-resolution structure of E. 
coli multidrug transporter emrD (Yin et al 2006) and the lower-resolution structure of           
O. formigenes OxlT (Hirai and Subramaniam 2004) have been resolved.  Structural analysis 
of MFS has also revealed that the 12 transmembrane domains of MFS protein are clustered 
into two halves of 6 transmembrane-domains, and that the two halves are pseudo-symmetric 
to each other with a pore between the clusters which is essential for substrate binding (Law et 
al 2008). In accordance with this view, the only MFS protein consisting of 6 transmembrane 
domains likely functions as a homodimer, whereas the MFS family with 24 transmembrane 
domains is likely to be a result of gene fusion event (Pao et al 1998, Saier 2003). 
Additionally, the two transmembrane domain clusters are separated by a long central loop, 
typically more than 30 residues, which is very important for efficient insertion of MFS protein 
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into biological membranes. It has also noted that the central loop is unlikely to be involved in 
transport activity, as the two clusters can be expressed separately and demonstrate similar 
transport activity as the wild type (Weinglass and Kaback 2000). 
 
 
1.6 Objectives 
Since its first genetic description on 2002 (Bodmer et al 2002), followed by 
confirmation of its putative lysosomal residence by a proteomics approach (Schroeder et al 
2007), there is no further study reported about the DIRC2. Hence, this study aims at the 
characterization of biochemical properties of the DIRC2 protein.  This includes verification of 
its lysosomal localization, trafficking, post-translational modification, processing of the 
protein and downregulation of its expression. 
This study takes an advantage from bioinformatic tools which help in the modelling of 
the topology of DIRC2, as well as in the designing of several DIRC2 mutants aimed at 
elaborating possible motifs, such as lysosomal targeting motif and glycosylation motif. 
Subcellular colocalization and trafficking of DIRC2 and DIRC2 mutants were investigated by 
using organelles immunostaining. In the course of this study, an intriguing fact was revealed 
that the DIRC2 is proteolytically processed. Efforts have been made to investigate the 
protease account for the DIRC2 processing. This involves the use of several protease 
inhibitors, from wide range protease inhibitors to specific protease inhibitors, to analyze the 
processing of DIRC2. Some mouse embryonic fibroblasts (MEFs) cells deficient in several 
proteases were also used to investigate the protease responsible for the processing of DIRC2. 
The results of this study are expected to be the first biochemical characterization of 
DIRC2, as well as an advance for further studies of other lysosomal transporter proteins. 
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2 Materials and Methods  
2.1 Materials 
2.1.1 Equipments  
Table 2.1.1 below lists the equipments used in this study 
Table 2.1.1 Equipments. 
Equipment Model Company 
Autoclave Tecnomara Integra Bioscience, Fernwald 
Agarose gel electrophoresis 
chamber 
(Mini) Sub-Cell GT BioRad, Hercules, USA 
Analytical balance Model 770-60 Kern and Sohn, Duerwangen 
 Sartorius Sartorius, Goettingen 
Binocular CKX41  Olympus, Tokyo, Japan 
Centrifuges Biofuge fresco Heraeus, Hanau 
 J6-HC Beckman, California, USA 
 J2-HS Beckman, California, USA 
 Centrifuge 5418 Eppendorf, Hamburg 
 Multifuge 3SR+ Heraeus, Hanau 
 Optima™ TLX 
Ultracentrifuge 
Beckman, California, USA 
 Optima™ LE-80K 
Ultracentrifuge 
Beckman, California, USA 
Density gradient fractionator Auto Densi Flow Labconco, Missouri, USA 
Fluorescence microscope Axiovert 200M Carl Zeiss, Jena 
Ice machine AF30 Scotsman, Illinois, USA 
Imager LAS-3000 mini Fujifilm, Carrolton, USA 
Electric pipette  Accu-jet
®
pro Brand, Wertheim 
Electroporator Gene Pulse BioRad, Hercules, USA 
Freezer -20
o
C Liebherr Liebherr, Bulle, Switzerland 
Freezer -80
o
C Hera Freeze Heraeus, Hanau 
Horizontal shaker KL2 Edmund Buehler, Hechingen 
 Swip  Edmund Buehler, Hechingen 
Incubator Certomat
®
H B. Braun Biotech 
International, Melsungen 
 Modell 200 Memmert, Schwabach 
 Orbital incubator Gallenkamp, Loughborough, 
UK 
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Liquid nitrogen tank Consartic Consartic, Schoellkippen 
Magnetic stirrer IKAMAG
®
REO ScienceLab, Houston, USA 
Microplate reader Sunrise™ Tecan, Männedorf, 
Switzerland 
 Synergi™ 4 BioTek, USA 
 Take 3Modul BioTek, USA 
Microwave NN-E245W China Panasonic 
pH- Electrode Digital-pH-Meter 646 Krick, Langenselbold 
Photometer GeneQuant pro Biochrom, Cambridge, UK 
 Nanodrop ND-1000 Peqlab Biotech, Erlangen 
Power supply PowerPac 200/300/HC BioRad, Munich 
Roller shaker RM 5  Assistent, Sondheim 
Refrigerator GKS 500 Wolfram Ungermann, Wetter 
SDS-PAGE electrophoresis 
chamber 
Mini-Protean 3 BioRad, Hercules, USA 
 Twin Model L Peqlab Biotech, Erlangen 
Semi dry protein transfer Trans-Blot
®
 SD-Cell BioRad, Hercules, USA 
Thermobloc Thermomixer 5436 Eppendorf, Hamburg 
Thermocycler GeneAmp Perkin Elmer, USA 
 PCR System 2400  
 Biometra
®
 Tpersonal Analytik Jena 
 Biometra
®
 TGRADIENT Analytik Jena 
Ultrasonicator Micro Ultrasonic Cell Kimble/Kontes 
 Disrupter KT-50 Vineland, USA 
UV-Documentation device Gel Jet Imager Intas, Goettingen 
UV light Reprostar CAMAG, Berlin 
Ultracentrifuge rotor JA 17 Beckman, California, USA 
 TLA55 Beckman, California, USA 
Vortex minivortex Heidolph, Kelheim 
Water purification Mili-Q Plus Ultra Pure Water 
System 
Milipore, Massachusetts,  
USA 
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2.1.2 Disposable materials 
Table 2.1.1 lists the materials used in this study 
Table 2.1.2 Materials. 
Material Type Company 
96-Well Microplate Flat bottom Sarstedt, Nuembrecht 
Blot paper Whatman Roth, Karlsruhe 
Culture dishes Ø 3.5, 6, 10 cm Sarstedt, Nuembrecht 
Gloves Rotiprotect-LATEX Roth, Karlsruhe 
 Rotiprotect-NITRIL Roth, Karlsruhe 
Lens paper No. 1019 Assistant, Sondheim 
Microscope cover glasses Ø 13 mm Assistent, Sondheim 
Microscope slides Menzel-Glaeser Thermo Scientific, 
Braunschweig 
Mini tubes 1.5 mL, 2.0 mL Sarstedt, Nuembrecht 
Conical tubes 15 mL, 50 mL Sarstedt, Nuembrecht 
Nitrocellulose membrane Protran Whatman, UK 
Parafilm Grösse M Pechiney Plastic Packaging, 
Chicago, USA 
Pipette tips Different sizes Sarstedt, Nuembrecht 
Serological pipettes 5, 10, 25 mL Sarstedt, Nuembrecht 
 
 
2.1.3 Cells  
2.1.3.1 Bacteria: 
Escherichia coli XL1-Blue (Stratagene, La Jolla, California, USA) endA1 gyrA96(nalR) thi-1 
recA1 relA1 lac glnV44 F'[ ::Tn10 proAB
+
 lacI
q
 Δ(lacZ)M15] hsdR17(rK
-
 mK
+
) 
 
 
2.1.3.2 Mammalian cells: 
Table 2.1.3 Mammalian cells used in this study. 
Cell Source/Reference 
HeLa (DSMZ, Deutsche Sammlung von Mikroorganismen und 
Zellkulturen/German Collection of Microorganisms and Cell 
Cultures, Braunschweig) 
Cos7  DMSZ, Braunschweig 
PS1
+/+
 wild type MEF De Strooper et al 1999  
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CathB
-/-
 MEF Halangk et al 2000; Reinheckel et al 2001 
Cath BL
-/-
 MEF Sevenich et al 2006 
Cath L
-/-
 MEF Roth et al 2000; Reinheckel et al 2001 
Cath D
-/-
 MEF Saftig et al 1995 
 
 
2.1.4 Chemicals 
Below is list of chemicals used. Common chemicals used for buffers and solutions are given 
separately in the section 2.1.11.  
Table 2.1.4 Chemicals used in this study. 
Chemical Company 
β-D-glucopyranoside Sigma-Aldrich, Taufkirchen 
Acrylamide/bis-acrylamide solution Roth, Karlsruhe 
Agarose Roth, Karlsruhe 
Ammonium persulfate Roth, Karlsruhe  
Bacto agar Roth, Karlsruhe 
Bacto pepton Roth, Karlsruhe 
Bafilomycin A1 Sigma-Aldrich, Taufkirchen 
Brefeldin A Sigma-Aldrich, Taufkirchen 
CA-074-Me cathepsin B inhibitor Biomol, Pennsylvania, USA 
Complete Protease Inhibitor Roche, Mannheim 
Dabco Sigma-Aldrich, Taufkirchen 
DMEM with L-Glutamine PAA, Pasching, Austria 
DMSO Roth, Karlsruhe 
dNTPs 2 mM Fermentas, St. Leon-Rot 
E-64 cysteine protease inhibitor Merck, Darmstadt  
Ethidium bromide 1% solution Roth, Karlsruhe 
Fetal calf albumin (FCS) PAA, Pasching, Austria 
FuGENE HD transfection reagent Roche, Mannheim 
Leupeptin Sigma-Aldrich, Taufkirchen 
Mowiol
®
4-88  Sigma-Aldrich, Taufkirchen 
NH4Cl Roth, Karlsruhe 
Non-fat milk powder Roth, Karlsruhe 
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Pefabloc Roth, Karlsruhe 
Penicillin-Streptomycin  PAA, Pasching, Austria 
Pepstatin A Sigma-Aldrich, Taufkirchen 
Percoll
®
 GE  Healthcare, UK 
PMSF Sigma-Aldrich, Taufkirchen 
TEMED Roth, Karlsruhe 
TRANSFERin siRNA trasnfection Polyplus, Strasbourg, French 
Turbofect transfection reagent Fermentas, St. Leon-Rot 
Vinblastine Lilly, Indiana, USA 
Yeast extract Roth, Karlsruhe 
Z-FY-CHO cathepsin L inhibitor II Calbiochem, San Diego, USA 
 
2.1.5 Plasmids 
1. pEGFP-N1 (Clontech) 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 pEGFP-N1. 
pEGFP-N1 vector encodes a red-shifted variant of wild-type GFP which has been optimized for brighter 
fluorescence (excitation maximum 488 nm and emission maximum 507 nm) and higher expression in 
mammalian cells. It has a classical pUC origin of replication (ori) for propagation in E. coli, and SV40 ori for 
replication in mammalian cells. The multi cloning site (MCS) of pEGFP-N1 is located between the pCMV 
promoter and the N-terminus of EGFP, which allows the EGFP tag to be conjugated at the C-terminus of the 
protein of interest. Cloning marker is provided by a neomycin-resistance cassette (Neor), consisting of the SV40 
early promoter, and the neomycin/kanamycin resistance gene of Tn5).  
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2. pEGFP-C1(Clontech) 
 
 
 
 
 
Figure 2.2 pEGFP-C1. 
The vector pEGFP-C1 is similar 
to the pEGFP-N1, except that the 
genes cloned into the MCS will 
be expressed as a fusion protein 
to the C-terminus of EGFP. 
 
 
 
 
 
 
3. pcDNA™3.1/Hygro(+) (Invitrogen) 
 
 
 
 
 
 
Figure 2.3 pcDNA3.1/Hygro+. 
The pcDNA3.1/Hygro+ vector is a mammalian 
expression vector. It has a CMV promoter and a 
hygromycin resistance coding gene and allows high level 
transient and stable expression in mammalian cells  
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2.1.6 Primers and Oligonucleotides 
Table 2.1.5 primers used to generate constructs in this study. 
Name of primer Oligonucleotide sequence 5’→  3’  Construct nr 
pEGFP.C1_DIRC2 Fw CATGCAAGATCTATGGGCTCTCGCTGGAGCA 2 
pEGFP.C1_DIRC2 Rv TAGAATTCTTAAACGGAGACAACCACAT 2 
CLN7_3xMyc_XhoI_Rev 
CCGCTCGAGTTACAGATCCTCTTCTGAGATGAGTTTTT
GTTCCAGATCCTCTTCTGAGATGAGTTTTTGTTCCAGA
TCTTCTTCAGAAATAAGTTTTTGTTCGGATCCTTCCTG
AATCCT 
All, except 
GFP construct 
CLN7_HindIII_Fw GCTTAAGCTTGCCACCATGGCCGGCCTGCGG All, except 
GFP construct 
DL5A1.Ext.F TCCCAATGGGACAGCCGCAGCTGCAGCTGCG 
GAGAGCAG 
9 
DL5A1.Ext.R CGCAGCTGCAGCTGCGGCTGTCCCATTGGGAGCTGG 9 
DL5A2.Ext.F CTCTTCTTGCTGCAGCGGCTGCAGCTGCAGCCATTAAA
GATC 
10 
DL5A2.Ext.R TGCTGCTGCTGCTGCTGCTGCAGCAAGAAGAGGTGAT
G 
10 
DL5A3.Ext.F AGCAGGGCGCATGCAGCGGCCGCAGCTGCGGCTGTGT
TA TAT 
11 
DL5A3.Ext.R TGCTGCTGCTGCTGCTGCATGCGCCCTGCTGCTCTCTG
C 
11 
mCtsB_HindIII_Fw CTAGAAGCTTATGTGGTGGTCCTTG 12 
mCtsB_XhoI_Rv CAGTCTCGAGTTAGAATCTTCCCCAG 12 
mCtsL_HindIII_Fw CTAGAAGCTTATGAATCTTTTACTC 13 
mCtsL_XhoI_Rv CAGTGAGCTCTCAATTCACGACAGGATAGC 13 
 
 
 
Table 2.1.6 DIRC2 siRNA (Stealth Select RNAi™, Invitrogen, CA, USA). 
Nr siRNA Oligonucleotide sequence 5’→  3’   
1 HSS131473 GGA GGC UGU GUU GUU GGA AUA GCU A  
2 HSS131474 UCU UGA AUA GCA GCG UGC CUA UAU U  
3 HSS131475 GCA GAA UUU GGA GUU GUC UGC UUA A  
    
    
2.1.7 Constructs 
Except otherwise indicated, all constructs below are placed in the multicloning site of 
pcDNA3.1 mammalian expressing vector  
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Table 2.1.7 Constructs used in this study. 
No Construct Constructor 
1 pEGFP-N1.DIRC2 Dr. B. Schroeder, Kiel 
2 pEGFP-C1.DIRC2 LRT Savalas, Kiel 
3 DIRC2-3xmyc Dr. B. Schroeder, Kiel 
4 DIRC2-N209A-3xmyc Dr. B. Schroeder, Kiel 
5 DIRC2-Ha214-3xmyc Dr. B. Schroeder, Kiel 
6 DIRC2-Ha261-3xmyc Dr. B. Schroeder, Kiel 
7 DIRC2-3xmyc-ERret Dr. B. Schroeder, Kiel 
8 DIRC2-LL/AA-3xmyc Dr. B. Schroeder, Kiel 
9 DIRC2-(Loop5 A1)-3xmyc LRT Savalas 
10 DIRC2-(Loop5 A2)-3xmyc LRT Savalas 
11 DIRC2-(Loop5 A3)-3xmyc LRT Savalas 
12 mCtsB LRT Savalas 
13 mCtsL LRT Savalas 
 
 
2.1.8 Antibodies 
2.1.8.1 Primary antibody 
Table 2.1.8 Primary antibodies used in Western blot or immunofluorescence. 
Antibody Source  Company/Source 
-Actin Rabbit Sigma-Aldrich, Taufkirchen 
-mCtsB AF965* Goat RD Systems, Wisconsin, USA 
-mCtsL AF1515* Goat RD Systems, Wisconsin, USA  
-hCtsB AF953* Goat RD Systems, Wisconsin, USA 
-hCathepsin D Mouse Prof. Dr. A. Hasilik, Marburg 
-mCathepsin D Rabbit  University of Goettingen 
-hCtsL AF952* Goat  RD Systems, Wisconsin, USA 
-hDIRC2 (epitope: GSRWSS      
EEERQPLLGPGLGPGLG) 
Rabbit Pineda, Berlin 
-h-β glucocerebrosidase Mouse Hans Aerts, Amsterdam 
-GFP Mouse Roche, Mannheim 
-HA-biotin 3F10 Rat Roche, Mannhein 
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-KDEL clon 10C3 Mouse Stressgen, San Diego, USA  
-KDEL receptor clon KR10 Mouse Stressgen, San Diego, USA 
-hLAMP-2 Mouse Prof. Dr. A. Hasilik, Marburg 
-mLAMP-2 ABL93 Rat DSHB, Univ of Iowa, USA 
-LBPA Mouse J. Gruenberg, Geneva 
-myc Rabbit Santa Cruz, California, USA 
-myc 9B11 Mouse Cell signaling, Danvers, MA, USA 
-PDI Rabbit Santa Cruz, California, USA 
-Tubulin-E7-beta Mouse DSHB, University of Iowa, USA 
*) Catalog numbering system of the RnD Systems 
 
 
 
2.1.8.2 Secondary antibody 
Table 2.1.9 Secondary antibodies used in Western blot or immunofluorescence. 
Antibody Source Company 
α-Rabbit-IgG AF350#, AF488#, AF594# Goat Molecular Probes, Oregon, USA 
α-Mouse-IgG AF350#, AF488#, AF594# Goat Molecular Probes, Oregon, USA  
α-Rat-IgG AF350#, AF488#, AF594# Goat Molecular Probes, Oregon, USA 
α-Rabbit-IgG HRP Donkey Santa Cruz, California, USA 
α-Mouse-IgG HRP Sheep Dianova, Hamburg 
α-Rat-IgG HRP Donkey Santa Cruz, California, USA 
#
) AF: Alexa Fluor, refers to the synthetic fluorescent dyes developed by the Molecular Probes, 
Oregon, USA (currently part of Invitrogen) 
  
 
 
2.1.9 Media 
Bacterial culture: 
Lysogeny Broth (LB) liquid media: 
 1% (w/v) tryptone 
 1% (w/v) NaCl 
 0.5% (w/v) yeast extract 
 Autoclaved at 121
o
C 
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LB plate 
1% (w/v) tryptone 
 1% w/v) NaCl 
 0.5% (w/v) yeast extract 
 2% (w/v) bacto agar 
 Autoclaved at 121
o
C 
Optional: for clone selection, appropriate antibiotic was added to the final concentration of 50 
g/mL of ampicillin or kanamycin. 
 
Cell culture 
 Dulbecco's Modified Eagle Medium (DMEM) with L-Glutamine 
 10% (v/v) fetal calf albumin (FCS) 
 100 I.U. Penicillin 
 100 g/mL Streptomycin 
 
2.1.10 Kits 
Table 2.1.10 Kits used in this study. 
Kit Product Company 
DNA recovery High Pure PCR Purification 
Kit 
Roche, Mannheim 
Plasmid isolation PureYield™ Plasmid 
Midiprep System 
Promega, Madison, WI, USA 
 Gen JET™ Plasmid 
Miniprep Kit 
Fermentas, St. Leon-Rot 
Protein determination BCA Protein Assay Kit Pierce, USA 
Reverse transcription kit RevertAid™ Fermentas, St. Leon-Rot 
RNA isolation NucleoSpin
® 
RNA II Macherey Nagel, Dueren 
Western blot detection  ECL™ Advance  GE Healthcare, UK 
 
 
2.1.11 Buffers 
Below are the buffer used in this study. Except otherwise stated, chemicals are obtained from 
Merck (Darmstadt), Roche (Mannheim), Roth (Karlsruhe), Serva (Heidelberg) or Sigma 
Aldrich (Taufkirchen) with “p.a.” grades 
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6 x Agarose gel electrophoresis loading buffer (Fermentas) 
 10 mM Tris-Cl, pH 7.6 
 0.03% Bromphenol blue 
 0.03% Xylene cyanol FF 
 60% Glycerol 
 60 mM EDTA 
 
5 x Cathepsin L buffer 
 400 mM NaOAc pH 5.5 
4 mM EDTA 
8 mM DTT  
 
5 x Endoglycosidase H buffer 
 0.5% SDS 
 5% NP-40 
 125 mM EDTA 
 250 mM Natrium acetat pH 5.5 
 
Iso-osmotic buffer 
 250 mM Sucrose 
 10 mM Tris-Cl pH 7.4 
 
Lysis buffer 
 50 mM Tris-Cl pH 7.4 
 150 mM NaCl 
 1% Triton X-100 
0.1% SDS 
1 x Complete protease inhibitor 
 4 mM Pefabloc 
 Pepstatin A 
 4 mM EDTA 
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1 x PBS  
137 mM NaCl 
2.7 mM KCl 
1.5 mM KH2PO4 
8.1 mM Na2HPO4 
 pH adjusted to 7.4 with HCl or NaOH 
 
4 x SDS-PAGE loading buffer (reductive) 
4 mL of 20% SDS 
2.4 mL of 1 M Tris-Cl (pH 6.8) 
400 µL of 1% Bromphenol blue 
1.2 mL H2O 
2 mL of 2 M DTT (freshly prepared) 
 
SDS Resolving gel buffer  
1.5 M Tris-Cl 
0.4 % SDS 
pH brought up to  8.8 with HCl 
 
10 x SDS Running buffer 
1.92 M Glycerol 
250 mM Tris-Cl 
35 mM SDS 
Volume adjusted to 1000 mL with dH2O 
 
SDS Stacking gel buffer  
 0.5 M Tris-Cl 
0.4 % SDS 
 pH brought up to 6.8 with dilute HCl 
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Stripping buffer 
2 % SDS 
62.5 mM Tris-Cl 
 pH brought up to 6.7 with HCl 
100 mM β-Mercaptoethanol (freshly prepared) 
 
Stripping buffer (mild stripping, Abcam) 
15 g glycine 
1 g SDS 
10 mL Tween 20 
pH adjusted to 2.2 with HCl 
Volume brought up to 1 L with dH2O 
 
50 x TAE buffer 
2 M Tris-Cl 
2 M Acetic acid 
100 mL 0.5 M EDTA  
Adjust pH to 8.0 
Volume brought up to 1000 mL with dH2O 
 
10 x TBS  
150 mM NaCl 
25 mM Tris-Cl 
pH brought up to 7.4 with HCl 
 
TBS-Tween  
1 mL Tween-20 
1000 mL 1 x TBS 
 
 
Western-Blot blocking solution 
 5 % Non-fat milk powder in TBS-Tween 
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2.1.12 Enzymes 
Table 2.1.11 List of enzymes used in this study. 
Enzymes Function  Company 
BglII Restriction (A^G A T C T)  Fermentas, St. Leon-Rot 
Dream Taq Polymerase  Fermentas, St. Leon-Rot 
EcoRI Restriction G^A A T T C  Fermentas, St. Leon-Rot 
Endoglycosidase H Hydrolysis of  N-linked 
oligosaccharides 
Roche, Mannheim 
PNGase  F Hydrolysis of N-glycan chains Roche, Mannheim 
Hind III Restriction  (A^A G C T T)  Fermentas, St. Leon-Rot 
Pfu polymerase Polymerase  Fermentas, St. Leon-Rot 
PfuUltra™ Polymerase Agilent/Stratagene, USA 
Recombinan human cathepsin L Cysteine protease Biozol, Massachusetts, USA 
Reverse transcriptase Synthesis of DNA from RNA Fermentas, St. Leon-Rot 
T4DNA ligase Ligase  Fermentas, St. Leon-Rot 
XhoI Restriction (C^T C G A G)  Fermentas, St. Leon-Rot 
 
 
2.1.13 Softwares and web-based tools  
Table 2.1.12 Softwares and web-based tools aided the analysis in this study. 
Software Product Company/Resource 
DNA analysis Lasergene DNASTAR, Madison, Wisconsin, USA 
Image processing Photoshop Adobe, California, USA 
 AxioVision Release 4.8 Carl Zeiss MicroImaging, Jena  
 Image-Reader LAS-3000 Fujifilm, Carrolton, USA 
Protein topology TMHMM http://www.cbs.dtu.dk/services/TMHMM/  
  (Krogh et al 2001)  
 I-TASSER http://zhanglab.ccmb.med.umich.edu/ 
(Zhang 2008, Roy et al 2010) 
N-glycosylation site 
prediction 
NetNGlyc 1.0 Server http://www.cbs.dtu.dk/services/NetNGlyc/ 
(Gupta et al 2004) 
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2.2 Methods 
2.2.1 Molecular biology 
 
2.2.1.1 Basic PCR 
Polymerase chain reaction (PCR) is a method to specifically amplify a certain 
fragment of DNA. This reaction mimics the polymerase reaction in vivo, in that it uses the 
DNA polymerase enzyme to synthesize a single strand DNA from nucleic acid precursors, 
complement to a single strand DNA template. It differs however, in that the DNA replication 
in living cells requires the activity of helicase to unwind the double helix DNA and the single-
strand DNA binding (SSB) protein to stabilize single strand DNA, whereas in PCR reaction 
the double stranded DNAs are unwinded by applying high temperature (94
o
C or higher), 
followed by a cooling process to faciliate the pairing of the targeted DNA fragment with 
primers (annealing step, 50
o
C to 56
o
C). Finally, by using DNA polymerase from the Thermus 
aquaticus (Taq polymerase) which is active at high temperature (72
o
C), the amplification 
process is taken placed. The primers in an in vivo reaction are of ribonucleic acid, snythesized 
by the primase, whereas in PCR reaction, the pimers are short double stranded DNAs which 
are chemically snyhtesized.   
 
 
 
Belows are the typical PCR mixture and the PCR program used: 
Table 2.2.1 Standard PCR Reaction mixture for 50 L volume PCR. 
Component Volume  
DMSO 2.5 L 
dNTPs (2mM) 5.0 L 
10 x DNA polymerase buffer 5.0 L 
Forward primer (10 M) 2.0 L 
Reverse primer (10 M) 2.0 L 
Template DNA (10 ngL) 5.0 L 
H2O  27.5 L 
Taq DNA polymerase (2.5 U/L) 1.0 L 
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Table 2.2.2 Standard PCR program.  
Temperature Time (minute) 
94
o
C  5 
94
o
C  1 
56
o
C 1 
72
o
C  Varies 
72
o
C  10 
10
o
C   
 
 
2.2.1.2. Fusion PCR 
Substitutions of a certain sequence of a gene with other sequence were carried out by fusion 
PCR. It involves several steps of PCR reaction to obtain the sequence of interest 
(schematically described in Figure 2.4). To minimize the systemic error which may be 
produced in an individual PCR reaction, the Pfu DNA polymerase was used in fusion PCR, 
instead of the standard Taq DNA polymerase. Pfu DNApolymerase has been  engineered 
from the hyperthermophilic archaeum Pyrococcus furiosus (Fermantas,St. Leon-Rot), and it 
has an advantage that it possesses 3'=>5' exonuclease (proofreading) activity, which enables 
the polymerase to correct nucleotide incorporation errors, with an overall fidelity 8 times as 
high as those performed by the standard Taq DNA polymerase. It has, however, a slower 
overall activity (around 2 minutes to synthesize 1 kb single strand DNA), so that a longer 
elongation time is required for each PCR cycle. 
 
Table 2.2.3 PCR mixture for fusion PCR. 
Fusion PCR  mixture  (PCR 1 and 2) Elongation PCR  mixture  (PCR 3) 
DMSO   2.5 L 
dNTPs (2mM)  5.0 L 
10 x Pfu polymerase buffer 5.0 L 
Forward primer (10 M) 2.0 L 
Reverse primer (10 M) 2.0 L 
Template DNA (10 ng/L) 5.0 L 
H2O    27.5 L 
Pfu polymerase (2.5 U/L)    1.0 L 
DMSO   2.5 L 
dNTPs (2mM)  5.0 L 
10 x Pfu polymerase buffer 5.0 L 
Forward primer (10 M) 2.0 L 
Reverse primer (10 M) 2.0 L 
Template DNA (10 ngL) 0.0 L 
H2O    32.5 L 
Pfu polymerase (2.5 U/L) 1.0 L 
25-40 cycles 
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Table 2.2.4 PCR program for fusion PCR. 
Temperature Time (minute) 
94
o
C  5 
94
o
C  1 
56
o
C 1 
72
o
C  3-5  
72
o
C  10 
10
o
C   
 
 
Figure 2.4 Fusion PCR strategy. 
The sequence depicted in grey will be replaced by the yellow sequence. Two primer pairs (Fw1 and Rv1; Fw2 
and Rv2) are used in the PCR 1 and PCR 2 to amplify the left and the right region of the targeted gene, 
respectively. Rv1 and Fw2 contain an overlap region (20 to 25 base pairs) which is required as a “self template” 
for the fusion PCR (PCR 3). The resulted fusion product was reamplified by using Fw1 and Rv2 primer pair 
(PCR 4) to ensure that the both ends contain the intended restriction sites which are important in the cloning step 
of the chimeric gene with an expression vector. 
 
35-40 cycles 
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2.2.1.3 Reverse transcription-PCR 
The analysis of gene expression at mRNA level was carried out by reverse 
transcription PCR. This reaction used mRNA as a template to synthesize its respective double 
strand DNA. mRNA expression analysis is important, for example, to observe to which 
extend the expression of a gene is downregulated by siRNA. RNA from mammalian cell was 
isolated according to the protocol on 2.2.1.9 and its concentration was determined by 
Nanodrop ND-1000 (Peqlab, Erlangen). The reverse transcription reaction was carried out 
according to the RevertAid™ manufacterer´s instruction (Fermentas, St. Leon-Rot) and 
summarized in the table below. 
 
Table 2.2.5 Reverse transcriptase reaction.  
Component Quantity Treatment 
RNA  x L (= 2.5 g)  
DEPC treated H2O (11-x) L  
Oligo dT 1 L Mixed and briefly centrifuged 
Incubated at 70
o
C  for 5 minutes 
Placed on ice and briefly centrifuged 
5X Reaction buffer 4 L  
RNAse inhibitor 1 L  
dNTP 2 L Mixed and centrifuged 
37
o
C for 5 minutes 
Reverse transcriptase 1 L 
(Total volume 20 L) 
Reaction at 42
o
C for 60 minutes 
Reaction stopped by heating at 70
o
C for 
10 minutes 
Sample kept on ice 
 
To analyze the result of the reverse transcription reaction, 2 L of reaction mixture 
was used as the template in a standard PCR reaction (2.2.1.1) and the PCR result was 
visualized on an agarose gel (2.2.1.5). 
 
2.2.1.4 DNA Isolation 
Isolation of DNA from living cells was undertaken either by the mini or midi DNA 
preparation procedures. They differ from each other in their scale and objective of the 
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preparation. Additionally, in a gel elution procedure, DNA is recovered after electrophoretic 
separation in an agarose gel (Gel elution 2.2.1.5). 
 
Mini DNA preparation (Gene JET™ Plasmid Miniprep Kit, Fermentas, St. Leon-Rot) 
Mini DNA preparation is used for the screening of E. coli colonies bearing plasmid 
DNA of interest. Following the transformation of E. coli, bacterial colonies spread out on an 
agar plate containing an antibiotic marker. Only E. coli colonies bearing recombinant plasmid 
DNA are expected to grow on a selective media. However, in false positive cases, linear 
vector are recircularized and regain their ability to grow on a selective media despite the lack 
of gene of interest. Several colonies of E. coli were picked up with sterile tooth picks and 
transferred into 3 to 5 mL LB medium containing an appropriate antibiotic. Bacteria were 
grown overnight (14 to 18 hours) at 37
o
C. On the second day, cells from individual colonies 
were harvested by centrifugation.   
A typical volume or 1.0 to 1.5 mL of culture was pelleted in a microcentrifuge (7.000 
x g for 5 minute at room temperature). The rest of medium was decanted, and cell pellet was 
resuspended by 250 L resuspension solution containing RNAse. Cells were lysed by 250 L 
of lysis solution containing SDS/alkaline and suspension was mixed by inverting 
microcentrifuge tube for 4-6 times. Plasmid DNA was neutralized by the addition of 350 L 
neutralization solution (mixed by inverting the microcentrifuge tube for 4-6 times). Cell 
debris and chromosomal DNA are pelleted in the next centrifugation step (12.000 x g, 5 
minutes) and lysate containing plasmid DNA is transferred into the spin column. Plasmid 
DNA will bind to the silica membrane in a spin column in the next centrifugation step. 
Plasmid DNA was washed twice with 500 L of wash solution containing ethanol followed 
by an empty centrifugation to ensure the removal of washing solution. Plasmid DNA was 
finally eluted by 50 L ultrapure H2O.  
An enzymatic restriction was usually performed to check whether the gene of interest 
is present in the plasmid DNA (Restriction assay 2.2.1.10). Plasmid DNA which was positive 
in the restriction assay was then sequenced to proof the correct sequence and framing of the 
gene of interest (2.2.1.8). 
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Midi DNA preparation (PureYield™ Plasmid Midiprep System, Promega, Madison, WI, USA) 
Expression study of a certain construct requires a substantially amount of plasmid 
DNA. This has been mostly achieved by the midi preparation of plasmid DNA. Individual 
clone of E. coli with sequence-proofed plasmid DNA was cultured in 50 to 100 mL LB media 
supplemented with an appropriate antibiotic. Culture was cultivated in 50 mL conical tubes 
and centrifuged at 3.500 x g for 15 minutes (room temperature). Cell pellet was resuspended 
with 3 mL resuspension solution and lysed with 3 mL lysis solution. The mixture was 
homogenized by inverting the tube 3-5 times.  To this mixture, 6 mL neutralization solution 
was added and the mixture was centrifuged at 15.000 x g for 15 minutes at room temperature. 
The resulted lysate was filtered through a filtering column (blue column) and the plasmid 
DNA in the overflow was trap in a binding column. The plasmid DNA was washed first with 
5 mL detoxification solution and followed by 20 mL ethanol-containing washing solution. 
The DNA was left air-dried prior to elution with 600 L ultra pure H2O. The concentration of 
the isolated plasmid DNA was determined by Take 3 Modul of BioTek Multiplate Reader. 
 
2.2.1.5 Agarose gel electrophoresis 
Following the PCR reaction or enzymatic cleavage, DNA needs to be purified from 
the unwanted products or contaminants.  This is achieved by first performing electrophoresis 
in an agarose gel, which separated the DNA according to the molecular weight, followed by 
the elution of DNA fragment from the agarose gel (see 2.2.1.6 below).  
Agarose gel electrophoresis is a simple way to separate DNA samples from their 
contaminants or undesired products. In this method samples DNA are separated according to 
their molecular weight. The supporting matrix through which the DNA samples were 
separated is made of a network of polysaccharide derived from seaweed powder (agarose). 
The typical concentration of agarose used to make the agarose gel lies between 1% to 2% 
(w/v) agarose in TAE buffer. Agarose powder was boiled in TAE buffer and cooled down to 
around 50
o
C. At this point, chelating dye ethidium bromide was added, which later aided the 
visualization of the DNA. The mixture was poured into a casting tray with a comb to provide 
sample pockets and let hardened. DNA samples were diluted with water and 6x loading dye 
and loaded into sample pockets. Separation of samples was achieved by applying 5V current 
per electrodes distance (cm). 
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2.2.1.6 Gel elution (High Pure PCR Purification Kit, Roche, Mannheim) 
DNA fragments resulted from PCR reaction or restriction enzyme digestions were 
eluted from agarose gel by High Pure Purification Kit (Roche, Mannheim). DNA band of 
interest was cut from the agarose gel and placed in a 1.5 mL microtube. 150 L isopropanol 
and 350 L of binding solution were added to the DNA fragment. The Mixture was incubated 
in Thermo bloc at 62
o
C until the gel was dissolved. The lysate was then transferred into spin 
column and centrifuged at 12.000 x g for 1 minute. DNA will bind to the silica matrix at the 
bottom of spin column. DNA was washed twice with 500 L and 200 L washing solution, 
sequentially, and finally eluted with 50 L ultrapure H2O. The purified PCR fragment can 
further be digested with restriction enzyme, or used in the fusion PCR, whereas the purified 
DNA from restriction reaction can be used in the ligation reaction (2.2.1.11). 
 
2.2.1.7 Determination of nucleic acid concentration 
The DNA concentrations of each plasmid DNA preparation were determined 
spectrophotometrically by GeneQuant Pro spectrophotometer (Biochrom, Cambridge, UK) or 
by the Take 3 Modul of BioTek Multiplate Reader (BioTek, USA). The RNA concentration 
was determined by the Nanodrop ND-1000 (Peqlab, Erlangen). The devices basically 
measured the absorption of the nucleic acids at 260 nm. Close to that wavelength, 
contaminant proteins also show a peak at 280 nm, so that the ratio of A260 to A280 nm 
indicated the purity of nucleic acid samples. For most application, the ratio A260/280 of 1.80 or 
higher met the requirement for further use of samples (plasmid DNA for cell line transfection 
2.2.3.3 or reverse transcriptase reaction 2.2.1.3). 
 
2.2.1.8 DNA sequencing 
The critical step in the molecular cloning is confirmation of the sequence of the gene 
of interest. Following the E. coli transformation by the ligation mixture and screening of E. 
coli colonies bearing the intended plasmid DNA and restriction digestion assay of the isolated 
plasmid DNA, the sequence of DNA needs to be determined. The DNA sequencing 
throughout this study was done by MWG Biotech (Martinsried) or GATC Biotech 
(Konstanz).  
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2.2.1.9 RNA isolation 
The total RNA isolation protocol referred to the NucleoSpin RNA
® 
II User Manual 
(Macherey Nagel, Dueren) optimized for mammalian cell culture. The basic principle of RNA 
purification using this kit resembles the isolation of DNA by the majority of commercial 
DNA isolation kits, except that a measure needs to be taken to prevent the degradation of 
RNA, and that there is an additional on-column DNA digestion by DNAse to allow only RNA 
is left in a spin column prior to elution step. 
The RNA isolation steps are described as follow: Cell pellet was lysed by chaotropic 
ions within the lysis buffer and filtered by the NucloeSpin
®
 Filter column. The lysate was 
homogenized with 70% Ethanol and transferred into the NucleoSpin
®
 RNA II Column.  Upon 
centrifugation, nucleic acids (RNA dan DNA) were bound to the silica matrix in the column. 
The high salt concentration which facilitates the nucleic acid binding in previous step was 
reduced by the membrane desalting buffer. On-membrane digestion of DNA was achieved by 
adding RNase-free rDNase for 15 minutes. The salt removal is important for the activity of 
the rDNase. Three washing steps were the carried out, and the RNA was finally eluted with 
RNase free H2O. RNA samples were stored in -80
o
C prior to further use. 
 
2.2.1.10 DNA digestion by restriction enzyme  
Restriction enzymes have the ability to cut a specific sequence of DNA. They are 
frequently used in molecular cloning to produce overhang at both 5’ and 3’ end of DNA 
fragment, which can later be fused with a linearized plasmid cut by the same restriction 
enzyme. The fusion of a DNA fragment with a vector is termed ligation reaction (2.2.1.11). 
In a typical cloning procedure, a certain sequence of DNA or a gene was amplified in 
a PCR reaction (2.2.1.1) by using a pair of primers with known restriction recognition sites. 
These recognition sites were included in the primers. The primers in this study were ordered 
from Sigma-Aldrich Genosys (Steinheim). The choice of the restriction enzyme recognition 
sites in the design of PCR primers took into account the recognition sites available in the 
multi cloning sites (MCS) of the plasmid vector, i.e. that the overhang ends of both DNA 
fragment and vector were compatible to each other, to ensure that the DNA fragment can be 
ligated to the vector. The restriction reactions were carried out overnight at 37
o
C. 
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Table 2.2.6 Digestion of DNA by restriction enzymes. 
Digestion of PCR fragment  Digestion of plasmid DNA (vector) 
Component Quantity   Component Quantity 
PCR fragment* 44 L  Plasmid DNA 1 g 
10 x buffer
#
 5 L  10 x buffer
#
 5 L 
RE 1 1 L (10 U)  RE 1 1 L (10 U) 
RE 2 1 L (10 U)  RE 2 1 L (10 U) 
H2O  50 L  H2O  50L 
*) eluted from agarose gel (2.2.1.6) 
#
) referred to the Fermentas buffers system (Fermentas, St. Leon-Rot). The buffer should be 
compatible to both restriction enzymes (RE) 1 and RE 2. 
 
 
2.2.1.11 Ligation 
The fusion of a DNA fragment with a linearized vector plasmid was carried out by the 
aid of T4-DNA ligase (Fermentas, ST. Leon-Rot). The prerequisite for a successful ligation 
reaction is that both DNA fragment and the linearized vector have to be compatible to each 
other, which is achieved by restriction reaction of both parts. The table below shows a typical 
ligation reaction of DNA fragment (PCR product, digested with restriction enzymes, and 
eluted from an agarose gel) with a vector plasmid (originally from 1 g plasmid DNA, 
linearized with the same restriction enzymes and eluted from an agarose gel). 
 
Table 2.2.7 Ligation reaction mixture. 
Component Ligation Control 
DNA fragment 6 L - 
Vector 2 L 2 L 
10 x Ligation buffer 1 L 1 L 
T4 DNA Ligase 1 L 1 L 
H2O - 6 L 
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Ligation reactions were undertaken by incubating the ligation mixture in a water bath 
of 17
o
C overnight. Reactions were terminated by incubation at 62
o
C for 10 minutes and the 
ligation reaction mixtures were used in E. coli transformation (Section 2.2.3.2) followed by 
the screening of bacterial colonies. 
 
2.2.1.12 Dephosphorylation 
In a ligation reaction, the linearized plasmid vector can recircularize and result in false 
positive identification in the screening of positive clones. This may be reduced or prevented 
by the use of alkaline phosphatase enzyme which cleaves the phosphate group either at the 5’ 
or at the 3’ end of DNA, prior to the ligation reaction. In this study, FastAP™ 
Thermosensitive Alkaline Phosphatase (Fermentas, St. Leon-Rot) was used. It has an 
advantage that it is compatible to all of Fermentas buffer system of the restriction enzymes 
which were used to produce overhang for ligation reaction. Hence, an electrophoresis and gel 
elution step is not necessary to perform. 1 g plasmid DNA was initially digested with 
appropriate restriction enzymes and recovered from an agarose gel. The linearized plasmid 
DNA was digested with 1 U FastAP™ Alkaline Phosphatase in a thermobloc of 37oC for 5 
minutes. The alkaline phosphatase was then inactivated by incubation at 75
o
C for 10 minutes, 
and the reaction mixture was finally ready to use in a ligation reaction. 
 
 
2.2.2 Biochemistry 
2.2.2.1 Total lysate preparation 
Proteins from transfected cells were isolated to analyze the expression of different 
DIRC2 constructs or effect of the use of siRNA. In a standard preparation, cells were 
harvested 32 hours to 48 hours post-transfection. In another application, cells were harvested 
earlier, for example in the investigation of effect of proteolysis inhibitors administration. 
To isolate the proteins, cells on a 10 cm Ø culture dishes were washed twice with ice 
cold PBS buffers, and then scrapped with 1 mL PBS containing 1 x complete protease 
inhibitor and 4 mM EDTA (accordingly, cells in a 3.5 Ø cm dishes were scrapped with 0.5 
mL such buffer). Cells were centrifuged at 1000 x g for 5 minutes at 4
o
C. At this stage, cells 
can be stored for further analysis or directly resuspended in the lysis buffer (2.1.11). Prior to 
disruption, the cells suspension was placed on ice for 1 hour. Disruption of the cells was 
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achieved by ultrasonication (2 x 10 seconds by a micro-ultrasonic cell disruptor 
Kimble/Kontes, Vineland, NJ). Lysate containing protein was separated from the cell debris 
by centrifugation at 13.000 x g for 10 minutes. 
 
2.2.2.2 Membrane protein preparation 
The membranic fraction of transfected cells was prepared as follows: cells were 
seeded in 4 dishes (10 cm), transfected by plasmid DNA (2.2.6.1) and harvested two days 
after transfection. Cells were washed two times with ice cold PBS, then scrapped in 1 mL iso-
osmotic buffer for each dish. Cells were centrifuged at 1.000 x g for 5 minutes (4
o
C). Cell 
pellet from individual tubes were pooled and resuspended in 1 mL iso-osmotic buffer. Cells 
were disrupted by pipetting through a 27G cannula (30x up and down) and the lysate was 
centrifuged at 1.500 x g for 10 minutes (4
o
C). The membranic fraction was gained by 
centrifugation of the resulted post nuclear supernatant (PNS) at 100.000 x g for 30 minutes. 
 
2.2.2.3 Protein determination 
Protein determination of the lysate was carried out according to the manual of the 
BCA Protein Assay Kit (Pierce, USA). The basic of this protein determination lies on the 
reduction of Cu
2+
 to Cu
1+
 in an alkaline environment by protein (known as biuret reaction). In 
the second reaction step, two molecules of bicinchoninic acid (BCA) within the assay kit react 
one Cu
1+  
ion which produces an intense purple color complex. Bovine serum albumin (BSA) 
proteins of different concentration were used as the standard in this protein determination. 
The color intensities of both sample and standards were determined by measuring their 
absorbance at 562 nm, after incubation of the reaction mixture at 37
o
C for 15 to 30 minutes.  
The sample protein concentration was calculated from the linear regression path produced by 
a set of standard BSA proteins.  
 
2.2.2.4 Percoll
®
 fractionation 
To analyze the cellular distribution of a certain protein, subcellular fractionation has 
been carried out. This was done by the Percoll
®
 fractionation which separated cellular 
components according to their density. Percoll
®
 consists of silica particles (15-30 nm in 
diameter) coated with non-dialyzable polyvinylpyrrolidone (PVP). Percoll
®
 is non-toxic, 
almost chemically inert and does not adhere to membranes. Upon centrifugation, it produces a 
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self-formed gradient from 1.0 to 1.3 g/mL, which makes it is highly versatile for many 
applications in the separation of biological samples. It has been long time used in the 
fractionation of many biological materials, such as sperma from semen, blood components, 
bacteria, viruses and subcellular components. 
In this study, subcellular distribution of the DIRC2 has been analyzed. HeLa cells 
were transfected with pcDNA3.1 DIRC2-3xmyc (4 x 10 cm dishes, each transfected with 2.5 
g plasmid DNA).  Cells were harvested 32 hours after transfection. Cells were washed two 
times with ice cold PBS buffer, then with homogenization buffer (250 mM sucrose, 10 mM 
HEPES pH 7.4, 1 mM EDTA, Complete protease inhibitor). Cells were scrapped from the 
dish in homogenization buffer. After centrifugation, cells were pooled in one microtube and 
resuspended in homogenization buffer. The lysis of cells was done by 10-12 up and down 
pipetting by a 27G cannula. PNS was separated from cells debris and nuclear by 
centrifugation at 1.000 x g for 5 minutes. PNS lysate was layered on the top of ultracentrifuge 
tube previously filled with 0.5 mL 2.5 M sucrose and 5.8 mL 17% Percoll
®
 (w/v). Gradient 
centrifuge was performed at 40.000 x g, 47 minutes (70.i.Ti rotor). Fractionation was carried 
out by pumping the sample using a density gradient fractionator (Labcono, USA). Sample 
was pumped out from the lightest fraction and aliqouted in a volume of 0.5 mL.  
Percoll
®
 fractions of DIRC2 transfected HeLa cells were subjected to SDS-PAGE and 
Western blot. DIRC2 was detected by an anti-myc antibody, and the Western blot results of 
percoll fractions were aligned with several organelle markers, such as cathepsin D and GC 
for the lysosomes, and PDI for the endoplasmic reticulum. The Western blot of Percoll
®
 
fraction was also aligned with the enzymatic activity assays of each fraction (Section 2.2.13). 
  
2.2.2.5 SDS-PAGE 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is an 
analytical method to separate protein samples in a polyacrylamide matrix. It offers an 
advantage that the protein samples can be separated according to their molecular weight. It, 
hence, enables an estimation of molecular weight of a certain protein, as well as the 
expression level of a protein of interest. This is especially true if further analysis by Western 
blot is performed (2.2.3.6), since overexpression of a protein in mammalian cell culture is not 
readily observable in a polyacrylamide gel. The use of SDS from the sample buffer (Laemmli 
buffer) in this method facilitates the formation of artificial molecular charges of proteins. As 
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almost all proteins are covered by SDS molecules, a total negative charge of protein is 
produced, and they move toward the anode during the progress of electrophoresis. 
In a standard sample treatment with Laemmli buffer, protein samples and Laemmli 
buffer are boiled for 5 to 10 minutes. However, in order to maintain the stability of the DIRC2 
protein structure, in most application the DIRC2 protein  were incubated with Laemmli buffer 
at 37
o
C for 10 minutes. Electrophoresis was undertaken at 100 V to 140 Volt in a Mini 
Protean 3 electrophoresis chamber (BioRad, Hercules, USA) or Twin Model L (Peqlab 
Biotechnology, Erlangen). Throughout this study, 10% resolving gels and 4.5% stacking gels 
were used and prepared according to the chart below.  
 
Table 2.2.8 Recipe for polyacrylamide gel. 
Component 10% Resolving gel 4.5% Stacking gel 
Resolving buffer 2.6 mL - 
Stacking buffer - 1.35 mL 
30% acrylamide solution 3.3 1.75 mL 
H2O 4.0 6.85 mL 
TEMED 30 L 30 L 
10% Ammonium persulfate 60 L 60 L 
Total Volume ~10 mL ~10 mL 
 
 
2.2.2.6 Western blot 
The immobilization of protein on a membrane before detection using antibody refers 
to protein blotting. The most popular application of this method is the Western blot.  
Practically, it is an analytical method which involves the separation of protein samples in a 
polyacrylamide gel (protein electrophoresis) followed by the transfer of protein from 
polyacrylamide gel onto a membrane surface. The membrane can either be a polyvinylidene 
fluoride or nitrocellulose membrane. 
In this study, proteins were separated by SDS-PAGE (2.2.3.5) and they were 
transferred onto a nitrocellulose membrane in a semi-dry transfer set up. The transfer process 
is schematically depicted in the Figure 2.5. Following the transfer, the nitrocellulose can be 
considered as the replica of the gel. Membrane was blocked overnight by 5% non-fat milk (in 
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TBS Tween buffer) in cold room. To detect the protein band of interest, incubation with the 
primary antibody specifically recognizes the protein or tag of protein of interest was 
undertaken. The primary antibody was diluted in 5% non-fat milk (in PBS Tween buffer) 
according to the manufacturer´s instruction (for commercial antibody). Alternatively, 
optimation of the dilution factor for the primary antibody was undertaken.  
 
 
 
 
 
 
 
 
 
 
Figure 2.5 Semi-dry transfer of protein. 
Proteins to be transferred were subjected into SDS-PAGE separation. Transfer onto membrane was done by 
semi-dry transblot (BioRad, Hercules, USA). 4 filter papers and nitrocellulose membrane were pre wet with 
semi-dry transfer buffer. Two filter papers were placed directly on the anode plate, followed by the nitrocellulose 
membrane and polyacrylamide gel. Two filter papers covered the gel, and cathode was connected on the top. 
Transfer of protein was achieved by applying electric current of 1 mA/cm
2
 membrane surface for 2 hours.  
 
After 3 x 10 minutes washing steps, the membrane was incubated with a second ary 
antibody which specifically recognizes the primary antibody. Finally, the membrane was 
washed 3 x 10 minutes with PBS Tween buffer, and luminogen reaction was carried out with 
ECL Advance solution (GE Healthcare, UK), and the bands on the membrane was 
photographed in LAS-3000 Imager.  
For further analysis with an alternative primary antibody, the membrane can be 
stripped to get rid of the previous primary antibody and the secondary antibody attached to it. 
The stripping process can either be undertaken by a harsh stripping or mild stripping solution 
(2.1.11). A harsh stripping solution was used if it is known that sufficient proteins are blotted 
on the membrane. The membrane was incubated in the harsh stripping buffer at 55
o
C with 
occasional shaking. The membrane was then washed with PBS Tween buffer. An alternative 
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stripping procedure provided by the mild stripping process. In this case, the membrane was 
incubated with mild stripping buffer for 5 to 10 minutes at room temperature, washed two 
times with PBS (10 minutes each) and two times with PBS Tween buffer (5 minutes each). 
After the stripping process, the blocking step was carried out again, followed by the primary 
and the secondary antibody incubations, and detection the protein of interest by luminogen 
reagents. 
 
 
2.2.2.7 Enzyme assays 
This section compiles the enzymatic reaction performed in this study. Enzymatic 
reactions related to molecular cloning (PCR, restriction, dephosphorylation and ligation) are 
described in 2.2.1.  
 
PNGase F digestion 
Sample protein was incubated with denaturing buffer (containing -mercaptoethanol) 
at 56
o
C for 5 minutes. Triton buffer was added as well as 1 x Complete protease inhibitor 
(Roche, Mannheim) and H2O to the sample to the total volume of 70 L. The sample was 
divided into two parts, the undigested control and the test. 2 L of PNGase F or steril H2O 
were loaded to the test and undigested control tubes, respectively, and both were incubated at 
37
o
C for at least 4 hours or overnight. Laemmli buffer was added to both sample and control 
tubes, and the sample was further analysis by SDS-PAGE and Western blot.   
 
Endoglycosidase H 
Sample protein of 20 to 100 g was mixed with 5 x Endoglycosidase H buffer and    
25 x Complete protease inhibitor (Roche, Mannheim). To that mixture, -mercaptoethanol 
was added to final concentration of 50 mM. Sample was digested with 2 L recombinant 
Streptomyces plicatus Endoglycosidase H (5mU/L, Roche, Mannheim) and H2O was added 
to undigested control. Incubation was completed overnight at 37
o
C. 
 
Lysosomal enzyme: -hexosaminidase activity 
Lysosomal enzyme activities were determined for the DIRC2 siRNA downregulated 
HeLa cell extracts or percoll fractions. 10 L of cell extract or percoll fractions was added to 
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100 L substrate solution (10 mM p-Nitrophenyl-2-acetoamido-2-deoxy--D-
glucopyranoside in citrate buffer). Reaction was carried out by incubation at 37
o
C for 15 
minute. The reaction was stopped by the addition of 261 L stop solution (0.4 M 
Glycin/NaOH, pH 10.4) and the extinction of the solution was measured at 405 nm.  
The activity of -hexosaminidase was formulated by the following equation: 
 
Activity (mU/mL) = 
dE x Total volume (L) x 1000 
Extinction coefficient x Sample volume x Incubation time 
 
The specific activity of sample was determined by dividing the activity with the protein 
content of the respective sample. 
 
Lysosomal enzyme: -galactosidase 
The -galactosidase activity of cell extract was determined as follows: 10 L of cell 
extract was added to 100 L of -galactosidase substrate solution (o-nitrophenyl--D-
galactopyranoside in citrate buffer). The reaction was stopped after 30 minutes incubation at 
37
o
C by the addition of 250 L stop solution. The extinction of solution was determined at 
405 nm, and the activity of -galactosidase was calculated similarly to the calculation of -
hexosaminidase activity. 
 
Lysosomal enzyme: -mannosidase 
The -mannosidase activities of cell extract was determinted as follows: 20 L of cell 
extract was added to 100 L -mannosidase substrate solution (10 mM p-Nitrophenyl--D-
mannopyranoside in citrate buffer). The reaction was stopped after 120 minutes incubation at 
37
o
C by the addition of 261 L of stop solution. The extinction of solution was determined at 
405 nm, and the -mannosidase activity of each sample were calculated similarly to the 
calculation of the -hexosaminidase activity. 
 
2.2.2.8 Immunofluorescence 
Subcellular analysis by visualization of target molecule to locate the occurrence or 
distribution of target molecule was carried out by immunofluorescence.  This technique 
              Materials and Methods  
46 
 
mostly relies on a specific interaction between the molecules of interest with its respective 
(primary) antibody. The molecules of interest can be either an endogenous protein/molecules 
or an overexpressed protein achieved by cell transfection. To locate the subcellular 
distribution of the targeted molecule, a secondary antibody, tagged with a fluorescent dye, 
was used. The secondary antibody interacts specifically with the first antibody, and hence 
gives a hint where the interaction takes place. 
Cells were seeded on coverslips. On the second day, cells were transfected with an 
appropriate plasmid DNA and TurboFect transfection reagent (Fermentas, St. Leon-Rot). 
Cells were fixed with 4% paraformyldehyde on the next day and stored in PBS buffer in 
refrigerator. If the incubation time needs to be prolonged, the cells were washed and new 
medium was added, and the cells were further incubated prior to fixation. 
Cells were permeabilized by incubation with 0.8% saponin (Roth) in PBS buffer for 5 
minutes, followed by incubation in 0.12% glycine fo 10 minutes. Cells were then washed with 
0.8% saponin and incubated for at least 15 min in 3% bovine serum albumin (BSA)/PBS 
buffer containing 0.8% saponin.  Incubation with the first antibody was undertaken in a 
humid-chamber. Antibodies were diluted in 3% BSA/PBS/0.8% saponin solution to 
appropriate dilutions and applied for 1 hour. The secondary antibodies, chromophore 
conjugated antibodies recognizing the primary antibodies, were applied after the primary 
antibody incubation, with several washing steps of the coverslips in between. The used 
antibodies are listed in the section 2.1. Cells were then washed 5 times in 0.8% saponin/PBS 
and 2 times in water. Coverslips were placed on a glass plate and finally mounted with 
moviol. Moviol contains DAPI for nuclear straining. Coverslips were protected from light 
exposure. Immunofluorescence analysis was carried out on an Axiovert 200M Zeiss 
fluorescence microscope. 
 
 
2.2.3 Cell biology 
The introduction of foreign plasmid DNA into bacterial cells is known as 
transformation, so called because the transformed bacteria acquire new properties which are 
determined by the new genetic information carried by the plasmid DNA. The purpose of this 
technique can either be the amplification of plasmid DNA, or employing bacteria as a 
production platform of protein encoded by genetic information within the plasmid DNA. Both 
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objectives can be achieved because the plasmid DNA is able to replicate within the bacterial 
host, and can be transferred from parental bacteria to their daughter cells. In this study, the 
objective of bacterial transformation is limited to the amplification of plasmid DNA. 
 
2.2.3.1 Preparation of electro-competent E. coli 
Bacterial cell walls are normally impermeable to the hydrophilic plasmid DNA. In 
order to permeabilize the bacterial cell walls, the bacteria have to be competent of taking up 
plasmid DNA when they are treated under electrical or heat shock. Bacteria used in this study 
are of the XL1-Blue strain of Escherichia coli (Stratagene) which have tetracycline resistance. 
Bacteria competent of taking up plasmid DNA under electrical shock (electro-competent 
cells) are prepared by inoculating a single colony of E. coli XL1-Blue in 50 mL Lysogeny 
Broth (LB) liquid media, followed by an overnight incubation in a shaking incubation 
chamber of 37
o
C. All LB media in the preparation of XL1-Blue electro-competent cells 
contain 50 g/mL tetracycline. On the next day, two aliquots of 25 mL of the preculture were 
transferred into 1 L LB medium in a 2 L flask. Incubation was continued until the optical 
density at 600 nm (OD600) of the cultures reaches 0.5 - 0.6, monitored by OD600 measurement 
with GeneQuant spectrophotometer. Once this point was reached, cells were cooled on ice 
with occasional shaking to ensure the homogenous cooling. Cells were divided into 4 x 250 
mL, each in a centrifuge tube, and then collected by cold centrifugation at 2.400 x g for 15 
minutes (JA14-Rotor, J2-HS centrifuge, Beckman). Cells were washed two times with ice 
cold sterile distilled H2O and centrifuged at 2.400 x g for 15 minutes. Cells were then washed 
with 20 mL ice cold 10% glycerol prior to centrifugation at 1.000 x g for 20 minutes. The 
resulted electro-competent cells were finally resuspended in 4 mL 10% (v/v) glycerol and 
aliquoted each in 50 L volume in a 1.5 mL microtube, frozen immediately with dry ice and 
stored in -80
o
C for further use.  
 
 
2.2.3.2 E. coli transformation 
Transformation of E. coli by means of electrical shock is called electroporation. In this 
process,  100 ng of plasmid DNA of known identity or 1 L of ligation product (section 
2.2.1.11) is mixed with 50 L electro-competent E. coli on ice. The mixture was transferred 
into a pre-chilled electroporation cuvette, and an electrical shock of 2.5 kV, 400  and 25 F 
of electroporator (BioRad, Hercules, USA) was applied. Transformation mixture was 
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immediately resuspended in 1 mL LB medium, and shaked in a thermobloc of 37
o
C for 45 
minutes. For retransformation of known plasmid DNA, 1 mL of transformation mixture was 
directly transferred into 50 mL LB medium containing an appropriate antibiotic (50 g/mL 
kanamycin or ampicillin), followed by an overnight incubation in a shaking incubator of 
37
o
C. The plasmid DNA from the retransformation process was isolated according to the 
DNA midi preparation protocol (section 2.2.1.4). For screening of ligation reaction, 200 L of 
transformation mixture was spread out on an LB agar plate containing an appropriate 
antibiotic, followed by an overnight incubation at 37
o
C. Several colonies from the screening 
LB agar plate were isolated according to the mini DNA preparation (section 2.2.1.4), and 
subjected to restriction assay to check whether they contain an intended DNA insert. 
 
2.2.3.3 DNA transfection 
The introduction of foreign DNA into a mammalian cell-line is called transfection.  
TurboFect™ transfection reagent (Fermentas, ST. Leon-Rot) was used in this study. It 
consists of cathionic polymer which complexes the DNA, and facilitates the up take up DNA 
through cell membrane. 
Cells were seeded on a culture dish in DMEM medium. On the second days, cells of 
around 70% confluency were transfected by DNA construct of interest. For HeLa cells in a Ø 
10 cm dish, 2.5 g DNA was added into 250 L pre-warmed DMEM medium (without 
penicillin/streptomycin). The DNA was mixed thoroughly, and 5 L TurboFect transfection 
reagent was added and placed in room temperature for 15 minutes. The tranfection mixture 
was added into the cells and the culture was incubated in a humid incubator of 37
o
C 
conditioned with 5% CO2. If the incubation time should be more than one day, the medium 
was changed 24 hours after the transfection, since the transfection reagent is commonly toxic 
to the cells when applied for a longer time. For transfection of cells in a 3.5 cm dish or for one 
well of 6-wells plate, 1 g plasmid DNA was diluted in 100 L DMEM medium, followed by 
the addition 2 L transfection reagent.  
 
2.2.3.4 siRNA transfection 
Transfection of mammalian cells by siRNA was carried out similarly to the 
transfection with DNA. A certain amount of siRNA was diluted in DMEM medium (without 
FCS or antibiotics penicillin/streptomycin). To that mixture, INTERFERin transfection 
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reagent (Polyplus, Strasbourg, French) was added and the mixture was incubated in room 
temperature for 15 minutes to allow the formation of complex of siRNA with the transfection 
reagent. The mixture was then added to 1-2 days old mammalian cells. The transfection 
scheme is summarized in the following table. 
 
Table 2.2.9 siRNA transfection mixture. 
Dish diameter (cm ) 20 M siRNA   Plain DMEM  
INTERFERin  
Reagent 
Vol DMEM (10% 
FCS + Pen/Strep) 
3.5 1 L 200 L 4 L 2.0 mL 
10.0 3.15 L 300 L 24 L 6.0 mL 
 
 
2.2.3.5 Protease inhibition in vivo 
In order to investigate whether a specific protease inhibitor has an ability to prevent 
the processing of the DIRC2 protein, inhibitory profiling of DIRC2 with several protease 
inhibitors have been tested. HeLa cells were initially transfected with DIRC2-3xmyc. Medium 
was changed 6 hours after transfection and inhibitors or relevant solvents were added into the 
cells. Cells were harvested 10 hours after the addition of protease inhibitors. Lysates were 
prepared and subjected into SDS-PAGE separation and further analyzed by Western blot.  
 
The following table list the protease inhibitor used in this study. 
Table 2.2.10 Concentrations of protease inhibitors in cells media. Sources of inhibitors are 
included in Table 2.1.4. 
Inhibitor (solvent) Function Concentration 
Brefeldin A1 (methanol) Inhibits protein transport out of ER 5 µg/mL  
NH4HCl (H2O) Lysosomes acidification inhibitor 25 mM  
Leupeptin (H2O) Serine and Cysteine  protease inhibitor 100 µM  
Pepstatin A (DMSO) Aspartyl protease inhibitor 1 µg/mL  
E-64 (H2O) Cysteine protease inhibitor 40 µM 
CA-074-Me (DMSO) Cathepsin B inhibitor 40 µM 
Z-FY-CHO (ethanol) Cathepsin L inhibitor 40 µM 
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 3. Results  
3.1 Analysis of DIRC2 sequence 
The 1434 bps long open reading frame of human DIRC2 gene corresponds to a protein 
of 478 amino acids. The sequence of DIRC2 protein shows a high degree of homology to 
known members of Major facilitator superfamily (MFS) proteins, such as human feline 
leukemia virus type C receptor (FLVCR) with 43% similarity within the amino acid region 
69-427, as well as homology to a number of putative MFS members, e.g. 50% similarity in 
amino acids 156-215 to inorganic phosphate cotransporter in Arabidopsis thaliana, 44% 
similarity in amino acids 278-433 to a putative transporter in Leishmania major (Bodmer et al 
2002). In silico analysis of DIRC2 sequence by TMHMM program 
(http://www.cbs.dtu.dk/services/TMHMM/, Krogh et al 2001) suggests a protein consisting of 
twelve transmembrane domains (Figure 3.1 A and B, transmembrane domains shaded in 
grey). The hydrophilic amino acids sequence between TM2 and TM3 also fits well to the 
signature sequence of proteins belonging to the MFS superfamily. Individual transmembrane 
domains consist of 20-23 amino acid residues (Figure 3.1 B). Furthermore, whereas the length 
of individual loops can vary and may contain post-translational modifications, the central loop 
between TM6 and TM7 (Figure 3.1 A, B) is predicted to be around 30 amino acid residues 
which represents the loop size usually found in members of MFS proteins. It is thought that 
this length is required for an efficient insertion of MFS protein into a membrane (Weinglass 
and Kaback 2000).   
 
It has been described in the introduction (Section 1.2) that at least three motifs are 
involved in lysosomal targeting of membrane proteins, i.e. DXXLL, DEXXXLLI and 
YXXØ motifs. The first two are referred to as dileucine motifs, whereas the latter are known 
as tyrosine-based motifs. Cation dependent and independent MPRs are examples of lysosomal 
proteins utilizing DXXLL motifs. The DEXXXLLI type sorting motifs are found e.g. in 
LIMP-2, sialin and GLUT8 proteins. The tyrosine-based motif YXXØ is present in LAMP-1, 
LAMP-2 and CD63 proteins. Sequence analysis of the DIRC2 protein revealed a potential 
dileucine lysosomal targeting motif –E9ERQPLL15-, which is located at the N-terminal end 
(Figure 3.1 A) and two putative tyrosine-based lysosomal targeting motifs at its C-terminal 
end (-Y467-D-RL470- and Y471-L-D-V474-). 
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Figure 3.1 Proposed topology of human DIRC2. 
(A) Human DIRC2 consists of 478 amino acid residues.  It is proposed to have 12 transmembrane spanning 
domains (highlighted in grey). The sequence shown in the box represents a dileucine lysosomal 
targeting motif (red box) and two potential tyrosine-based motifs (black box).  Asn209 is part of a 
putative N-glycosylation site (open head arrow). A synthetic peptide (underlined sequence) was used to 
generate a rabbit anti hDIRC2 antiserum.  
(B) Topology prediction of DIRC2 generated by TMHMM server 
(http://www.cbs.dtu.dk/services/TMHMM/, Krogh et al 2001). According to this model, DIRC2 
consists of twelve transmembrane spanning domains, with both termini facing the cytosol and a putative 
glycosylation site in the lumen of lysosomes (N209). Two sites of internal HA tags are shown by arrow 
heads.  The epitope used to raise an anti human DIRC2 antiserum in rabbit is depicted along with a 
dileucine motif close to the N-terminal end of DIRC2.  
(C) Schematic representation of DIRC2 constructs. 
A 
 
B 
 
C 
DIRC2-3xmyc
DIRC2-HA214-3xmyc
DIRC2-HA261-3xmyc
DIRC2-N209A-3xmyc
GFP-DIRC2
DIRC2-GFP
DIRC2-3xmyc-ERret
DIRC2-LL/AA-3xmyc
GFPDIRC2 DIRC2 epitope HA N209A3xmyc
Color legend:
LL/AA ERret
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N-glycosylation modification is a common post-translational modification of proteins 
exhibiting a consensus sequence of Asn-X-Ser/Thr (X represents any amino acid residue, 
except proline), although not all such sequences are used for N-glycosylation (Medzihradszky 
2008; Brooks et al 2006). The DIRC2 sequence shows two such consensus sequences, i.e. -
N209-G-T211- and -N394-S-S396-.  The first putative N-glycosylation site was analyzed whether 
it is used (Section 3.4), whereas the second N-glycosylation motif was not explored, since it is 
located within a predicted transmembrane region and is unlikely to be used. 
 
 
 
 
 
 
Figure 3.2 Expression of GFP and 3xmyc-tagged DIRC2 analyzed by Western blot. 
Two GFP-tagged constructs of DIRC2, pEGFP.C1-DIRC2 and pEGFP.N1-DIRC2 (GFP-DIRC2 and DIRC2-
GFP, respectively), as well as DIRC2-3xmyc and empty vectors were expressed in HeLa cells. Cells were 
harvested 24 hours after transfection. Lysates were prepared as described in the Materials and Methods. Aliquots 
of total lysates (10 g and 15 g for GFP-tagged and -3xmyc tagged DIRC2, respectively) were subjected to 
SDS-PAGE and Western blot analysis.   
(A) Detection of GFP-tagged DIRC2 proteins was carried out by an anti-GFP primary antibody followed by 
HRP-conjugated secondary antibody. GFP-DIRC2 fusion shows an apparent molecular weight of about 55 kDa, 
whereas DIRC2-GFP fusion appears at about 45 kDa.  
(B) DIRC2-3xmyc expression detected with anti-DIRC2 recognizing the N-terminal part of DIRC2. The 
uppermost bands of about 55 kDa and a slightly smaller band of around 50 kDa may represent the modified and 
unmodified form of full length DIRC2, respectively. The band of about 35 kDa is presumably the N-terminal 
fragment of DIRC2 which contains its sugar rest 
(C) The nitrocellulose membrane in (B) was reprobed with anti-myc antibody recognizing the 3xmyc tag at the 
C-terminal end of DIRC2. The bands of about 55 kDa and 50 kDa represent the modified and unmodified full 
length DIRC2, respectively. The band of about 26 kDa is likely the C-terminal fragment of DIRC2.   
 
 
 
A B C 
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3.2 DIRC2 is proteolytically processed 
Expression analysis of DIRC2 was carried out in transiently transfected HeLa cells 
with either GFP or 3xmyc tagged DIRC2 constructs (Figure 3.1 C). Cell lysates were 
analyzed by Western blot. Interestingly, different bands were observed for overexpressed 
DIRC2 when it was tagged with GFP at the N- and C-terminus, respectively (Figure 3.2 A). 
GFP-DIRC2 showed a band of about 55 kDa, whereas DIRC2-GFP appeared at molecular 
weight of about 45 kDa. Both fusion proteins were detected at a lower apparent molecular 
weight as predicted (from the fusion of DIRC2 with GFP), which is expected to be about 75-
80 kDa. This suggests that DIRC2 protein is likely to be proteolytically processed. 
The expression of 3xmyc tagged DIRC2 provides substantiation that DIRC2 is 
proteolyzed. Figure 3.2 B and C show the expression of DIRC2-3xmyc detected with an 
antibody against the N-terminal epitope and 3xmyc tag at the C-terminus of DIRC2, 
respectively. In both cases, full length DIRC2 appears at a molecular weight of about 55 kDa, 
and a slightly lower band whose apparent size is approximately close to the calculated 
molecular weight of 52.1 kDa of the core polypeptide of DIRC2. However, detection with the 
anti DIRC2 antibody shows an additional band at a molecular weight of about 35 kDa, 
whereas detection with anti-myc antibody reveals a band at a molecular weight of about 26 
kDa. Both smaller bands are likely to represent proteolytic products of DIRC2, which may 
correspond to the bands at about 55 kDa and 45 kDa when DIRC2 was fused to GFP (Figure 
3.2 A).  
 
3.3 DIRC2 is a lysosomal membrane protein 
DIRC2 has been identified in a sub-proteomic study as a putative lysosomal 
membrane protein (Schroeder et al 2007). In order to experimentally confirm the lysosomal 
localization of DIRC2, DIRC2-3xmyc was expressed in HeLa cells and detected with 
antibodies against the N-terminal epitope and 3xmyc tag at the C-terminus by indirect 
immunofluorescence. Figure 3.3 shows that signals for both the N-terminal epitope and C-
terminal 3xmyc tag colocalize with the lysosomal membrane protein LAMP-2 (A-C and D-F, 
respectively). As expected, DIRC2 detected by antibody against the 3xmyc also colocalizes 
with another lysosomal marker protein -glucocerebrosidase, GC (G-I) and with a late 
endosomal lipid Lysobiphsosphatidic acid, LBPA (J-L). This result suggests that DIRC2 is a 
lysosomal membrane protein.  
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DIRC2 is a lysosomal membrane protein Figure 3.2
E LAMP-2 F Merge
A DIRC2 B LAMP-2 C Merge
D Myc
DIRC2-3xmyc
DIRC2-3xmyc
Construct 
G Myc H GC I Merge
J Myc K LBPA L Merge
DIRC2-3xmyc
DIRC2-3xmyc
Lysosomal localization of DIRC2 could also be demonstrated by subcellular 
fractionation of HeLa cells transiently transfected with DIRC2-3xmyc. Cells were disrupted 
mechanically by passage through a 27G cannula in an iso-osmotic buffer. Post nuclear 
fraction (PNS) was obtained by centrifugation at lower speed (1.000 x g). PNS was separated 
by density gradient centrifugation employing a self-forming Percoll
®
 gradient, with a starting 
concentration of 17% (w/v) Percoll
®
 and centrifugation at 40.000 x g for 47 minutes. 
Fractions were collected from the resulting gradient from top to bottom. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Localization of DIRC2. 
HeLa cells were transfected with DIRC2 constructs tagged with 3xmyc at the C-terminus. Cells were fixed and 
double stained with primary antibodies recognizing the N-terminus of DIRC2 and the lysosomal marker protein 
LAMP-2 (A-C) or with primary antibody recognizing the C-terminal 3xmyc tag and lysosomal markers LAMP-2 
(D-E), GC (G-I), and  late endosomal lipid LBPA (J-L). Both N- and C-terminal detection of DIRC2 
colocalizes with the lysosomal/late endosomal markers. Of note, the primary antibody against the N-terminus of 
DIRC2 does not detect endogenous DIRC2 (A). Bars represent 10 m. 
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Figure 3.4 Percoll
®
 fractionation of the extract of HeLa cells transiently transfected with DIRC2-3xmyc. 
HeLa cells were transfected with DIRC2-3xmyc and harvested 48 hours after transfection. Cells were disrupted 
and suspended in iso-osmotic buffer. Cell homogenate was fractionated in a self-forming Percoll
®
 gradient (17% 
w/v) upon centrifugation at 40.000 x g for 47 minutes.  
(A) Enzymes activities of -hexosaminidase and alkaline phosphatase were determined in each fraction 
using spectrophotometric methods as described in Materials and Methods. 
(B) Equal volumes of each fraction were subjected to SDS-PAGE and Western blot analysis. Western blot 
detection of each fraction was undertaken with several subcellular markers. DIRC2, as detected by anti-
myc, is shown to be co-sedimenting with lysosomes. It is recovered in the dense fractions (12-14), as 
shown by lysosomal markers LAMP-2, cathepsin D and βGC. A minor amount of DIRC2 is distributed 
in fraction 6 and 7 where the signal of ER marker PDI appears. 
Figure legend: LAMP-2: lysosomal associated membrane 
protein type 2; PDI: protein disulfide isomerase; CtsD:  
cathepsin D; βGC: beta-glucocerebrosidase. 
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Figure 3.4 A shows the distribution of lysosomal enzyme -hexosaminidase, which is 
found in the dense fractions (fraction 12-14). In contrast, activity of alkaline phosphatase, an 
enzyme of the plasma membrane, was recovered in two peaks in fractions 1-2 and fractions 4-
5, respectively. Parallel to this observation, the immunoblot analysis of individual fractions of 
HeLa cells transfected with DIRC2-3xmyc is depicted in Figure 3.4 B. It is revealed that 
proteolytically processed DIRC2 with a molecular weight of 25 kDa is observed in fraction 
12-14 co-sedimenting with lysosomes as indicated by the lysosomal markers LAMP-2, 
cathepsin D and -glucocerebrosidase. The discrepancy between theoretical and apparent 
molecular weight of DIRC2 (55 kDa and 25 kDa, respectively) suggests that DIRC2 may 
have been proteolytically processed. Nevertheless, the rather weak signals that presumably 
represent full length DIRC2 are observed co-sedimenting with the endoplasmic reticulum 
(fraction 5-7, shown by ER marker PDI). Taken together, both immunofluorescence and 
subcellular data confirmed the lysosomal localization of DIRC2 protein. However, further 
evidence is required to validate whether the processing of DIRC2 first takes place when it 
reaches lysosomes. 
 
3.4 DIRC2 is N-glycosylated at Asn-209 
Bioinformatics analysis of the DIRC2 sequence (Section 3.1) highlighted the 
possibility that DIRC2 may undergo N-glycosylation. Expression of DIRC2 in HeLa cell 
analyzed by Western blot (Section 3.2) also indicated that DIRC2 is expressed at an apparent 
molecular weight higher than the calculated molecular weight. In order to confirm whether 
DIRC2 is N-glycosylated, the lysate of HeLa cells overexpressing DIRC2-3xmyc was treated 
with N-glycosidase F (PNGase F). PNGase F is an amidase isolated from Flavobacterium 
meningosepticum that cleaves between the innermost N-acetyl-D-glucosamine (GlcNAc) and 
asparagine residues of high mannose, hybrid, and complex oligosaccharides from N-linked 
glycoproteins (Maley et al 1989). It is shown that wild-type DIRC2 is sensitive to PNGase F 
digestion (lane 3 and 4, detected by anti-hDIRC2 and anti-myc in Figure 3.5 A and 3.5 B, 
respectively). This result suggests that DIRC2 is an N-linked glycosylated protein. 
A closer view on the expression of wild-type, undigested, DIRC2 -upon detection with 
anti hDIRC2 antibody- (lane 3 Figure 3.5 A) revealed that wild-type DIRC appears in three 
forms: a band of about 55 kDa which represents the full length DIRC2 with its sugar moiety, 
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a band of about 35 kDa which represents the N-terminal half with a sugar moiety, and the 
small band slightly lower than the 25 kDa marker, which is supposed to be the deglycosylated 
N-terminal half of DIRC2. Incubation of wild-type DIRC2 in the presence of PNGase F (lane 
4 Figure 3.5 A) confirmed the identity of the full length DIRC2 bands, as removal of sugar 
moiety by PNGase F allowed the identification of the core polypeptide of DIRC2 of about 50 
kDa. Additionally, upon PNGase F digestion, the 35 kDa band completely disappeared and 
shifted to a band slightly below 25 kDa, thus confirming that the 35 kDa and 25 kDa bands 
are the glycosylated and the unglycosylated N-terminal half of DIRC2, respectively. This 
suggests that Asn-209 is used for N-glycosylation. On the other hand, redetection of the same 
blot with an anti-myc antibody revealed that the undigested DIRC2-3xmyc appears as two 
bands: the upper band of 55 kDa which fits the molecular weight of full length DIRC2 and a 
smaller band above 25 kDa protein marker, which is likely to be the C-teminus fragment of 
DIRC2 (Figure 3.5 B, lane 3). Upon PNGase F digestion, the full length DIRC2 was shifted to 
50 kDa which represent the core polypeptide DIRC2, whereas the C-terminal fragment was 
not shifted (Figure 3.5 B, lane 4). This validates that Asn-394 in the C-terminal half of DIRC2 
is not used for N-glycosylation.  
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Deglycosylation of DIRC2 by PNGase F. 
Wild-type DIRC2-3xmyc and DIRC2-N209A-3xmyc were overexpressed in HeLa cells. Cells were harvested 2 
days after transfection. Lysates were incubated in the presence or absence of PNGase F prior to SDS-PAGE 
separation and Western blot analysis as described in the Materials and Methods. 
A) Immunodetection of the full-length DIRC2 and its N-terminal fragment of both wild-type and N209A mutants 
of DIRC2 with antibody directed against N-terminal epitope.  
(B) Immunodetection of the same blot with an anti-myc antibody. Loading controls as well as PNGase F 
digestion control are provided by immunodetection of cathepsin D. 
Equal loading and control of PNGase F digestion were shown by cathepsin D detection (A and B). 
A B 
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A direct proof that the first N-glycosylation motif (-N209-P-T211-) is instead used for 
glycosylation was shown by analyzing the expression of DIRC2-N209A-3xmyc mutant.  In 
this mutant, Asn-209 is replaced by Ala-209 (construct provided by Dr. B. Schroeder). Lysate 
of HeLa cells expressing this mutant was incubated with PNGase F and analyzed by Western 
blot. Figure 3.5 A and B (Lane 5 and 6) revealed that both full length and fragments DIRC2 
appear at the same molecular weight as that apparently shown by PNGase F digested wild-
type DIRC2 (lane 4), irrespective of PNGase F digestion. These patterns are in agreement 
with the prediction that Asn-209 not Asn-394 is used for N-glycosylation. Moreover, 
validation of N-glycosylation site gave an indirect substantiation of the topology of DIRC2 
(Figure 3.1). The DIRC2 topology suggests that the loop 5 (region between TM5 and TM6 
where the N-glycosylation site located) resides on the luminal face of the membrane, whereas 
both N-terminal and C-terminal are facing the cytoplasmic environment. 
 
3.5 Lysosomal targeting of DIRC2 depends on a lysosomal sorting motif at its N-
terminus 
3.5.1. Expression of dileucine and ER retention mutants of DIRC2 
The targeting of proteins into lysosomes, as described in the Introduction (Section 
1.2), is defined by several lysosomal sorting motifs. One subclass of lysosomal targeting 
motifs is the consensus sequence DEXXXLLI (Table 1.1). Sequence analysis of DIRC2 
protein reveals that such a motif resides in its N-terminal region, namely –E9ERQPLL15-. In 
order to analyze whether this motif has a functional relevance for the lysosomal targeting of 
DIRC2, a DIRC2 mutant was constructed where the dileucine in the putative lysosomal 
targeting motif was replaced by alanines (LL/AA mutant, Figure 3.1 C). Expression of this 
mutant is shown in Figure 3.6 D-F.  It is revealed that replacement of the dileucine motif with 
alanines resulted in surface expression of DIRC2. This mutant showed very few or no 
colocalization with the lysosomal marker LAMP-2 (Figure 3.6 D-F). On contrary, disruption 
of two tyrosine-based lysosomal targeting motifs close to C-terminal end of DIRC2 (Figure 
3.1 B) had only minor effect on the lysosomal targeting of DIRC2 (data not shown). It is 
concluded that the dileucine motif is important for the lysosomal targeting of DIRC2. This 
observation underlines the critical importance of the dileucine motif of DIRC2 in the sorting 
of DIRC2 to the lysosomes. 
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Subcellular fractionation of HeLa lysate transfected with DIRC2 indicated that the 
majority of DIRC2 was distributed in lysosomal fraction in processed form, whereas only a 
small amount of DIRC2 co-sedimented with ER in full-length form (Section 3.3, Figure 3.4 
B). In order to validate that the absence of processed form of DIRC2 in the ER fraction was 
not due to the minor distribution of DIRC2 in ER, a DIRC2 mutant appended with RR-based 
ER targeting motif (DIRC2-3xmyc-ERret, Figure 3.1. C) was generated and overexpressed in 
HeLa cells. Expression of this mutant in HeLa cells, analyzed by immunofluorescence, 
resulted in an ER localization (Figure 3.6 J-L). This mutant appeared as a full length form on 
Western blot (M). It was likely to be retained in the ER or transported back from Golgi to the 
ER, and was not able to reach lysosomes (G-I). This result suggests that the ER retention 
motif predominantly retains the DIRC2 in the ER, irrespective of the presence of functional 
dileucine lysosomal targeting motif. This observation along with the result of subcellular 
fractionation (Figure 3.4 B) underlined the fact that DIRC2 was not fragmented in the ER, and 
that the processing had to occur in a post ER compartment.     
 
3.5.2 Stepwise post-translational modification of DIRC2 
Analysis of DIRC2 expression or localization in the ER can also be achieved by 
addition of brefeldin A1 to cultured cells. Brefeldin A has long been known to have an ability 
to inhibit the transport of protein out of the ER, although the rate of protein biosynthesis itself 
is not affected (Misumi et al 1986). In agreement to the function of brefeldin A, expression of 
DIRC2 in the presence of brefeldin A1 prevents proteolysis of DIRC2. Hence, it is concluded 
that DIRC2 is not proteolytically processed in the ER (Figure 3.6 M lane 3). It is also shown 
that the full length DIRC2 expressed in ER had a lower molecular weight in comparison to 
the full length DIRC2 expressed in the lysosomes (Figure 3..6 M lane 2). 
In order to analyse the glycosylation of DIRC2, wild-type and N209A mutant DIRC2 
were overexpressed in HeLa cells in the presence and absence of brefeldin A1. The lysates 
were treated with either PNGase F or Endo-β-N-acetylglucosaminidase H (Endo H). The 
latter cleaves oligosaccharides directly linked to an asparagine residue but not of complex 
oligosaccharides form (Maley et al 1989). Figure 3.7 shows the expression of wild-type 
DIRC2-3xmyc and DIRC2-N209A-3xmyc mutant in HeLa cells in the absence and the 
presence of brefeldin A1. As expected, addition of brefeldin A1 prevented the proteolytic of  
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Figure 3.6 Immunofluorescence analyses of dileucine and ER retention mutants of DIRC2. 
HeLa cells were transfected either with dileucine and ER retention mutants (DIRC2-LL/AA-3xmyc and DIRC2-
3xmyc-ERret, respectively; Figure 3.1 C). For immunofluorescence assay, transfected cells were fixed two days 
after transfection.  The DIRC2 LL/AA mutant was mainly expressed at the cell surface (D-F) and did not 
colocalize with the lysosomal marker LAMP-2. The DIRC2 ER retention mutant did also not colocalize with the 
lysosomal marker LAMP-2 (G-I). Instead, it colocalized with the endoplasmic reticulum marker KDEL (J-L). 
Figure A-C shows control of wild-type DIRC2-3xmyc overexpressed in HeLa cells. Bars represent 10 m. For 
Western blot analysis (Figure M), DIRC2-3xmyc was expressed in HeLa cells in the presence of brefeldin A1, 
which was added 6 hours after transfection to a final concentration of 5 g/mL. Cells were harvested 10 hours 
after brefeldin A1 addition. DIRC2 ER retention mutant as well as wild-type and empty vector were also used to 
transfect HeLa cells, and cells were harvested 16 hours after transfection. Aliquots of lysates (20 g protein) 
were subjected to SDS-PAGE and Western blot analysis as described in the Materials and Methods. Blot was 
detected with anti-myc primary antibody followed by HRP-conjugated secondary antibody. Equal loading was 
shown by actin detection (Figure M, lower panel).  
M 
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D Myc E LAMP-2
A Myc B LAMP-2 C Merge
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DIRC2-LL/AA-3xmyc 
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both wild-type and N209A mutant of DIRC2 (Figure 3.7 lane 12-19). On the opposite, both 
DIRC2 and N209A mutant of DIRC2 were processed in the absence of brefeldin A1 (Figure 
3.7 lanes 1-10). In all cases, the full length form of DIRC2-N209A-3xmyc mutant showed a 
molecular weight of about 50 kDa, irrespective of PNGase F and Endo H digestion (lane 3-4, 
7-8, 14-15, and 18-19). In the absence of brefeldin A1, the glycosylated full length and the C-
terminal fragment of wild-type of DIRC2 appeared as heterogeneous cluster of bands at 
molecular weight higher than 55 and a band of 25 kDa, respectively (Figure 3.7 lane 2, 6 and 
9). The wild-type DIRC2 expressed in the absence of brefeldin A1 was sensitive to PNGase F 
digestion (lane 1), but hardly sensitive to Endo H digestion (lane 5), reflecting that only a 
minor amount of DIRC2 is retained in the ER (and hence sensitive to Endo H digestion). In 
the presence of brefeldin A1, the wild-type DIRC2 shows a molecular weight slightly lower 
than 55 kDa (lane 13 and 17). However, this band was clearly shifted upon digestion with 
both PNGase F and Endo H (lane 12 and 16, respectively). This was a hint that DIRC2 
acquired its core glycans in the ER, and a further modification of its sugar is occurring in the 
post ER compartment. 
 
Figure 3.7 Post-translational modification of DIRC2 takes place in multiple steps. 
HeLa cells were transfected with DIRC2-3xmyc wild-type and DIRC2-N209A-3xmyc in the presence and 
absence of 5 g/mL brefeldin A. Cells were washed 6 hours after transfection and brefeldin A1 was added into 
the new medium. Cells were harvested 10 hours after the addition of brefeldin A1. Cell lysates were digested 
with PNGase F and Endo H as described in the Materials and Methods. The digested samples and undigested 
controls were subjected to SDS-PAGE separation and Western blot detection with an anti-myc antibody 
recognizing the C-terminally appended epitope tag wild-type and N209A mutant of DIRC2. 
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3.6 Detection of endogenous DIRC2 
 It has been shown that overexpressed DIRC2 in HeLa cells can be detected by anti-
hDIRC2 antibody recognizing an epitope at the N-terminus of DIRC2 (Figure 3.2. B). In 
order to validate whether anti-hDIRC2 antibody is able to detect DIRC2 at the endogenous 
level, anti-hDIRC2 antibody was used to detect DIRC2 from HeLa lysates transfected either 
by DIRC2 siRNAs or non-targeting siRNA.  Control lane in Figure 3.8 B shows that 
endogenous DIRC2 from HeLa cell can be detected by the anti-hDIRC2 antibody. The 
endogenous DIRC2 appeared as a cluster of bands between 30 to 40 kDa. This cluster of 
bands resembles the N-terminal half of overexpressed DIRC2-3xmyc detected by an anti-
hDIRC2 antibody (Figure 3.5 A lane 3). This result suggests that endogenous DIRC2 is 
glycosylated and proteolytically processed in a similar way as the overexpressed DIRC2.  
 
By using three different DIRC2 siRNAs or combination of them, DIRC2 can be 
significantly downregulated as shown by the reduction of DIRC2 mRNA and protein level 
(Figure 3.8 A and B, respectively). Following DIRC2 downregulation, expression level of 
several lysosomal marker proteins (LAMP-2, -glucocerebrosidase and cathepsin D) and 
activities of lysosomal enzymes (-hexosaminidase, -galactosidase and -mannosidase) 
were tested. Both types of analyses could not reveal significant alterations of either lysosomal 
marker proteins or lysosomal enzymes activities following DIRC2 downregulation by siRNA 
(Figure 3.8 C and D, respectively). Immunofluorescence analysis of DIRC2 siRNAs 
transfected HeLa cells revealed no apparent morphological alteration of cells and lysosomes 
or alteration of lysosomal storage (e.g. cholesterol, tested by filipin staining) (data not 
shown). 
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Figure 3.8 Downregulation of DIRC2 with siRNA. 
HeLa cells were grown on 10 cm dishes and transfected with DIRC2 siRNA (Stealth pre-design oligo siRNA, 
Invitrogen) on the second day to the final concentration of 10 nM. Transfections were achieved by TRANFERin 
siRNA transfection reagent (PolyPlus, Strassbourg, French). Analysis of mRNA level of DIRC2 was undertaken 
by first isolating the total RNA of the transfected cells 48 hours after siRNA transfection, followed by reverse 
transcriptase reactions using aliquots of the isolated total RNA as templates (RevertAid, Fermentas, St. Leon-
Rot).  
(A) The relative amount of DIRC2 mRNA levels was then determined by PCR with a primer pair which 
amplifies full length DIRC2 sequence from the reverse transcriptase reaction mixture. Control for this 
analysis was provided by analyzing the mRNA level of a house-keeping gene GAPDH (exon7-8).  
(B) siRNA transfected HeLa cells were harvested 48 hours after tranfection and the lysates were subjected 
to SDS-PAGE separation and Western blot analysis. Expression level of DIRC2 following DIRC2 
siRNA transfection was detected by using anti-hDIRC2 antibody. The N-terminal fragment of DIRC2 is 
shown by the cluster of bands at 30 to 40 kDa in control, non-targeting, siRNA lane. Asterisk shows 
unspecific band. 
(C) Expression of lysosomal proteins LAMP-2, βGC and Cathepsin D. 
(D) Activities of lysosomal enzymes β-hexosaminidase (β-hex), β-galactosidase and -mannosidase. 
A C 
B D 
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3.7 Inhibitory profiling indicates involvement of the lysosomal cysteine protease    
cathepsin L 
In an attempt to unravel the identity of the protease(s) involved in DIRC2 proteolysis, 
DIRC2 was overexpressed in HeLa cells in the presence of several protease inhibitors. An 
initial screening with a broad panel of inhibitors excluded, for example, a role of proteosome, 
aspartyl peptidase and -secretase in the fragmentation of DIRC2 (tested by MG132, pepstatin 
A and inhibitor X, subsequently; data not shown). On the contrary, prevention of DIRC2 
proteolysis was observed in DIRC2 transfected cells treated with NH4Cl and leupeptin. 
Effects of these inhibitors are shown in the Figure 3.9 lane 3 and 4, respectively. NH4Cl is 
known to interfere with the acidification of lysosomes (Gahl and Tietze 1985; Galbiati et al 
2000), which implied that the fragmentation of DIRC2 takes place in the lysosomes, and 
acidic environment is a prerequisite for a successful proteolysis. Leupeptin is known as a 
competitive serine/cysteine protease inhibitor (Aoyagi et al 1969). Pepstatin A, an inhibitor 
for aspartyl protease (Umezawa et al 1970), did not inhibit the proteolysis of DIRC2 (lane 5). 
These observations opened the possibility that DIRC2 is proteolyzed by lysosomal acid 
hydrolases of serine or cysteine protease class.  
 
 
 
 
 
 
 
 
 
Figure 3.9 Inhibition of DIRC2 proteolysis. 
HeLa cells were transfected with DIRC2-3xmyc in DMEM medium supplemented with 10% FCS and 
penicillin/streptomycin. Medium was refreshed six hour after transfection and inhibitors were added to final 
concentrations of 25 mM, 100 M and 1 g/mL for NH4Cl, leupeptin and pepstatin A, respectively. Cells were 
harvested 10 hours after the addition of inhibitors. Cells lysates were subjected to SDS- PAGE followed by 
Western blot analysis. Expression of DIRC2 was detected by a mouse anti-myc antibody. Equal loading was 
confirmed by detection of actin. 
     1      2      3      4       5 
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Lysosomes are harbouring a variety of hydrolases, including serine/cysteine proteases. 
Most of them are known as cathepsins. Members of this group include cathepsin A and G 
(serine protease), cathepsin B, C, F, H, K, L, O, S, W, V and Z (cysteine protease). 
Additionally, there are also cathepsin D and E which are known as lysosomal aspartic 
proteases (Reiser et al 2010). Further refinement was attempted by the use of additional, more 
specific, inhibitors. It is shown in the Figure 3.10 lane 4 that E-64 was able to inhibit the 
proteolysis of DIRC2. E-64 was reported to inhibit mostly cysteine proteases (Barrett et al 
1982, Katunuma and Kominami 1995). Hence, the result of proteolysis inhibition assay with 
E-64 ruled out the role of serine protease, and suggests a protease involved in the processing 
of DIRC2 which belongs to the cysteine protease group.  
Cathepsin B and L are two prominent cysteine proteases in lysosomes. In order to 
investigate their possible role in the processing of DIRC2, an experiment by using CA-074-
Me and Z-FY-CHO, inhibitors of cathepsin B and cathepsin L, respectively, was performed. 
Figure 3.10 lane 6 and 8 shows that both cysteine protease inhibitors were able to prevent the 
fragmentation of DIRC2. It suggests that cathepsin B and/or cathepsin L may be involved in 
the proteolysis of DIRC2. 
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Figure 3.10 Inhibition of DIRC2 proteolysis by cysteine protease inhibitors. 
HeLa cells were tranfected with DIRC2-3xmyc in DMEM medium supplemented with 10% FCS and 
penicillin/streptomycin. Medium was refreshed six hour after transfection and inhibitors were added into the 
cells to final concentrations of 100 M for leupeptin, and 40 M for E-64 (in H2O), CA-074-Me (in DMSO) and 
Z-FY-CHO (in ethanol). The effects of the solvent of inhibitors were shown by the addition of equivalent 
volumes of solvents (DMSO and ethanol; lane 5 and 7, respectively) to the transfected cells. Cells were 
harvested 10 hours after the addition of inhibitors. Cells lysates were subjected to SDS-PAGE separation and 
analyzed by Western blot. Expression of DIRC2 was detected by anti-myc antibody. Equal loading was shown 
by detection of actin. 
 
3.8 Processing of DIRC2 is abolished in Cathepsin L deficient fibroblasts 
 In order to dissect the contribution of different cathepsins, various murine embryonic 
fibroblast (MEF) cell-lines deficient in one or more cathepsins were utilized. Since lysosomal 
targeting is a prerequisite for proteolysis of DIRC2, an immunofluorescence analysis was first 
performed to ensure that the transected DIRC2-3xmyc localized in the lysosomes of cathepsin 
deficient MEFs. DIRC2-3xmyc construct was used to transiently transfect cathepsin B
-/-
, 
cathepsin L
-/-
, cathepsin BL
-/-
 MEFs, as well as wild-type and cathepsin D
-/-
 MEFs. It was 
revealed from figure 3.11 that human DIRC2 was localized in the lysosomes of all MEF cells 
tested. Therefore, these cells can be employed in the experimental set-up whether or not 
DIRC2 proteolysis was impaired in the absence of individual cathepsins.  
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7.B. Lysosomal colocalization of DIRC2 in protease-deficient fibroblasts 
WT
CtsB -/-
CtsL -/-
CtsBL -/-
CtsD -/-
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Figure 3.11 Localization of hDIRC2 in cathepsin deficient MEFs. 
DIRC2-3xmyc was used to transfect different MEF cell-lines deficient in one or two cathepsins (cathepsin B, 
CtsB
-/-
; cathepsin L, CtsL
-/-
; cathepsin B and L, CtsBL
-/-
, cathepsin D, CtsD
-/-
) as well as wild-type MEF. Cells 
were fixed with 4% paraformaldehyde 24 hours after transfection, permeabilized with 0.2% saponin and blocked 
with 3% BSA. DIRC2 expressions were visualized by anti-myc antibody, whereas lysosomes were stained by 
anti-LAMP-2 antibody. Nuclei were stained by DAPI (blue). Bars represent 10 m. 
 
Figure 3.12 shows the expression of DIRC2-3xmyc in cathepsin deficient MEF cell-
lines. DIRC2-3xmyc expressed in wild-type MEF cells (lane 4) showed a similar pattern to 
the DIRC2-3xmyc expressed in HeLa cells (lane 2): the full length DIRC2 appears at about 55 
kDa and the C-terminal fragment appears at about 25 kDa. Among the cathepsin deficient 
MEF cells, it was revealed that DIRC2-3xmyc was not proteolyzed in the cathepsin L 
deficient and cathepsin B and L double deficient MEF cells   (CtsL 
-/-
 in lane 8 and CtsBL
-/-
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10, respectively). In contrast, DIRC2-3xmyc was proteolyzed similar to wild-type cells in 
cathepsin B single deficient MEF (lane 6) and cathepsin D deficient MEF (lane 12). This 
result ruled out a role of cathepsin B and D in the proteolysis of DIRC2 and showed that 
cathepsin L is indispensable for the proteolysis of DIRC2 in MEF cells. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 Expression of DIRC2 in cathepsin deficient MEFs. 
Murine embryonic fibroblast (MEF) cells deficient in cathepsin B (CtsB
-/-
), cathepsin L (CtsL
-/-
), cathepsin B 
and L (CtsBL
-/-
) and cathepsin D (CtsD
-/-
) were transfected with DIRC2-3xmyc. Controls were DIRC2 expressed 
in HeLa and wild-type MEF. Cells were harvested 48 hours after transfection. Aliquots of cell lysates (20 g 
protein) of each sample were subjected to SDS-PAGE followed by Western blot detection. The full length 
DIRC2 and its C-terminal fragment (detected by anti-myc antibody) are shown by closed and opened arrow 
heads, respectively. There was no proteolytic fragment of DIRC2 observed when DIRC2 was expressed in either 
cathepsin L single deficient or cathepsin B and L double deficient MEF (upper panel). Lower panels confirm the 
absence or presence of respective cathepsins in different cell-lines.  
 
It has been described above that overexpression of human DIRC2 in cathepsin L 
deficient MEFs prevents the processing of DIRC2. It is to be expected that endogenous 
DIRC2 is not processed in murine tissue deficient in cathepsin L. Murine DIRC2 has a similar 
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sequence to human DIRC2 with about 95% identity. The sequence of synthetic oligopeptide 
used to generate anti human DIRC2 antibody in rabbit (-G2SRWSSEEE RQPLLGPGLG 
PGLG24-, Figure 3.1 A) was very similar to the N-terminal sequence of mouse DIRC2 (-
G2SGWSSEEE ERQPLLGPGL GPAP24-) so that a cross-reactivity of the antibody against 
hDIRC2 with murine DIRC2 was expected. In order to investigate whether endogenous 
DIRC2 in cathepsin L knockout mouse was also proteolyzed, lysosome-enriched fractions 
from mouse liver was analyzed by Western blot.  The lysosome-enriched samples (tritosomes) 
were obtained from Dr. Markus Damme (University of Goettingen) and were prepared by 
injecting tyloxapol (Triton WR1339) into mice 4 days prior to sacrifice. This treatment alters 
the density of mouse lysosomes and facilitates an easy separation of highly-enriched 
lysosomes from the lysates of mouse livers. Details of this preparation were recently 
published (Damme et al 2010).  
  
 
 
 
 
 
 
Figure 3.13 Expression of endogenous mouse DIRC2 in wild-type and CtsL
-/-
 mouse liver. 
Lysosome-enriched liver lysates (tritosomes) of wild-type mouse and mouse deficient in cathepsin L livers were 
provided by Dr. Markus Damme (University of Goettingen). Aliquots of untreated and PNGase F treated 
tritosomes (1.5 µg protein) were subjected to SDS-PAGE separation and Western blot analysis. Blot was 
detected by anti-hDIRC2 which also recognized murine DIRC2. Full length murine DIRC2 was hardly detected 
in wild-type mouse liver tritosomes (lane 1), whereas in CtsL
-/-
 mouse liver tritosomes a small fraction of DIRC2 
was detectable (lane 3, shown by a closed arrow). In both wild-type and CtsL
-/-
 mouse liver, their bulk of DIRC2 
was present at a cluster of bands with an apparent molecular weight of 30 kDa (open arrow) that shifted to a 
band of about 20 kDa upon PNGase F digestion (lane 2 and 4, respectively). The PNGase F digested full length 
DIRC2 from CtsL
-/- 
mouse liver
 
was represented in a band of about 40 kDa (lane 4). The presence and the 
absence of cathepsin L in the wild-type and knockout mouse liver, respectively, were shown by detection with 
anti-mouse cathepsin L (lower panel). 
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 Unlike the result shown by overexpressing of human DIRC2 in MEF cells deficient 
in cathepsin L, DIRC2 was proteolyzed to a significant degree and only a small amount of full 
length DIRC2 appeared in endogenous CtsL
-/-
 mouse liver (Figure 3.13 lane 3 shown by 
opened and closed arrows, respectively). Both full length and processed forms of mouse 
DIRC2 were shifted to bands of about 40 and 20 kDa upon PNGase digestion, respectively 
(lane 4). In contrary, lysosome-enriched fractions from wild-type mouse liver showed very 
few or no full length DIRC2 (lane 1). The bulk N-terminal fragment of DIRC2 from wild-type 
mouse was shifted from 30 kDa to 20 kDa upon PNGase F digestion (lane 1 and 2, 
respectively). There was no observable PNGase F digestion product of full length DIRC2. 
The fact that DIRC2 processing in CtsL
-/-
 mouse liver is only slightly impaired indicates that 
the role of cathepsin L in the proteolysis of DIRC2 in CtsL
-/- 
liver may be compensated by one 
or more unknown proteases. 
 
3.9 Rescue of DIRC2 proteolysis by coexpression of cathepsin L in cathepsin deficient 
MEF 
 In order to substantiate the role of cathepsin L in the proteolysis of DIRC2, a rescue 
experiment was undertaken. Human DIRC2-3xmyc was co-expressed with mouse CtsL 
cDNA in CtsL
-/- 
MEF. Mouse CtsL cDNA was cloned in the pcDNA3.1 vector and used in 
co-transfection experiment. Co-expression of DIRC2-3xmyc together with mCtsL in CtsL
-/- 
MEF showed that mCtsL had the ability to rescue the proteolysis of DIRC2 (Figure 3.14 lane 
2). The rescue of DIRC2-3myc proteolysis by co-expression of mCtsL was abolished in the 
presence of cathepsin L inhibitor Z-FY-CHO (Figure 3.14 lane 3), in spite of expression of 
mCtsL (lower panel).  
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Figure 3.14 Rescue of DIRC2 processing in cathepsin L deficient MEF. 
Murine cathepsin L cDNA was inserted in a mammalian expression vector pcDNA3.1/Hygro+. Cathepsin L 
deficient, CtsL
-/-
 MEF cells were transfected with DIRC2-3xmyc; DIRC2-3xmyc and murine cathepsin L, 
mCtsL; DIRC2-3xmyc and mCtsL in the presence of 40 M cathepsin L inhibitor Z-FY-CHO (lane 1, 2, and 3, 
respectively). Cells were harvested 48 hours after transfection. Aliquots of cell lysates (20 g protein) were 
separated in 10% gel SDS PAGE and transferred onto nitrocellulose membrane. DIRC2 expression was detected 
by an anti-myc antibody. Rescue effect of co-expression of human DIRC2 and mouse cathepsin L was shown by 
presence of a DIRC2 C-terminal fragment of 25 kDa (lane 2). Transient mouse cathepsin L expression was 
detected by anti-mCtsL antibody (lower panel).  
 
 
3.10 Determination of the DIRC2 cleavage site 
 The initial Western blot data showed that DIRC2 was fragmented into two-halves  
approximately in the middle region of the protein (Figure 3.2 and 3.5). It was also determined 
that the N-terminal fragment of DIRC2 contains a sugar moiety, reflecting that the proteolysis 
site must be located after N209 (Figure 3.1). In addition, Figure 3.5 showed that cleavage of 
DIRC2 was independent of its glycosylation. In order to identify the cleavage site within 
DIRC2, several DIRC2 mutants were constructed, overexpressed in HeLa cells and analyzed 
by immunofluorescence and Western blot. Two DIRC2-3xmyc constructs with internal 
hemagglutinin (HA) tags, DIRC2-HA214-3xmyc and DIRC2-HA261-3xmyc, respectively, were 
generated and expressed in HeLa cells. The HA tags were inserted in the down-stream 
position of N-glycosylation site (loop 5) and in the middle of loop 6 for DIRC2-HA214-3xmyc 
and DIRC2-HA261-3xmyc constructs, respectively (Figure 3.1. C). Expression of the both 
internal HA constructs revealed similar protein bands for both full length and processed form 
                                                                                                                                                                                     Results 
72 
 
of DIRC2, detected either with anti-hDIRC2 and anti-myc  (Figure 3.15 A, left and right 
panels, respectively). These bands were also similar to the expression of wild-type DIRC2-
3xmyc. However, detection of the same blot with anti-HA antibody shows that, additionally 
to the full length DIRC2, DIRC2-HA214-3xmyc had a fragment of the same molecular weight 
as the N-terminal fragment of DIR2 (Figure 3.15, middle panel; N-terminal fragment is 
shown by asterisk), whereas DIRC2-HA261-3xmyc had a fragment of the same molecular 
weight as the C-terminal fragment of DIRC2. This result suggests that the amino acid residues 
214 and 261 are part of the N- and C-terminal fragment of DIRC2, respectively. 
Consequently, the fragmentation of DIRC2 seems to occur between amino acids 214 and 261.  
 According to the predicted topology of DIRC2 (Figure 3.1 B and shown in 3.15 B), 
the amino acid 214 is located in the loop 5 of DIRC2. Loop 5 and loop 6 of DIRC2 are 
located in the lumen of lysosomes and in the cytosol, respectively. It has been shown that 
lysosomal cysteine protease cathepsin L is critical for processing of DIRC2. It is therefore 
reasonable to consider that the processing of DIRC2 takes place in the loop 5 where 
lysosomal cathepsins are able to exert their function. To test this hypothesis, three alanine 
mutants were generated (DIRC2-6A1-3xmyc, DIRC2-6A2-3xmyc and DIRC2-6A3-3xmyc, 
Figure 3.15 B), expressed in HeLa cells and analyzed by Western blot and 
immunofluorescence. Whereas the first two mutants (DIRC2-6A1-3xmyc and DIRC2-6A2-
3xmyc) showed similar band patterns to that shown for wild-type DIRC2 (Figure 3.15 C lane 
1 and 2, respectively), the mutant with alanine substitution close to the TM6 segment 
(DIRC2-6A3-3xmyc mutant) was present mainly as full length precursor (lane 3). The 
appearance of this full length precursor suggests an ER-localization, since no cluster of band 
as in the case of fully glycosylated full length DIRC2 was observed. Figure 3.15 D confirmed 
that this mutant hardly localized to lysosomes, and instead localized to the ER (lysosomes and 
ER were detected by anti-LAMP-2 in the upper panel and anti-KDEL in the lower panel, 
respectively).  This result suggests the critical role of the boundary region between loop 5 and 
the TM6 of DIRC2 for lysosomal targeting (and hence processing of DIRC2). The ER 
localization of this mutant may also be attributed to the significance of the boundary region of 
loop 5 and TM6 for proper folding of protein or to pass the quality control function of ER.  
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Figure 3.15 Expression of internal HA-tagged and alanine mutants of DIRC2. 
(A) Two internally HA-tagged DIRC2 appended with 3xmyc constructs, DIRC2-HA214-3xmyc and DIRC2-
HA261-3xmyc were expressed in HeLa cells. Cells were harvested 24 hours after transfection and lysates 
(20 µg protein) were subjected to SDS-PAGE separation and Western blot analysis. Blot was detected 
with anti-hDIRC2, anti-HA, and anti-myc. Arrow head (middle figure) shows the N-terminal fragment 
of DIRC2 whereas cluster of bands in the left figure show N-terminal half of DIRC2 detected by anti-
hDIRC2. Asterisks show unspecific bands. 
(B) Amino acids in the loop 5 of DIRC2 were replaced by three short alanines sequences designated as 
DIRC2-6A1-3xmyc, DIRC2-6A2-3xmyc and DIRC2-6A3-3xmyc. 
(C) The three alanines mutants were transfected into HeLa cells. Cells were harvested 24 hours after 
transfection. Lysates (20 µg protein) were subjected to SDS-PAGE and Western blot analysis. Blot was 
detected with anti-myc antibody. The full length DIRC2 forms of DIRC2-6A1-3xmyc and DIRC2-6A2-
3xmyc appear as strong and difused bands at about 55 kDa (lane 1 and 2). The full length, ER-form of 
DIRC2-6A3-3xmyc shown by a band at about 50 kDa was the predominant form over they processed 
form. 
(D) DIRC2-6A3-3xmyc mutant analyzed by immunofluorescence. In the majority of transfected cells, 
DIRC2 localized to ER as shown by detection of KDEL (lower panel) and not localized to lysosomes as 
shown by detection of LAMP-2 (upper panel). Bars represent 10 µm.  
DIRC2-6A3-3xmyc 
DIRC2-A3-3xmyc Mutants expressed in HeLa Cells
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D Myc
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B LAMP-2
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3.11 Overexpression of GFP-tagged DIRC2 and formation of enlarged/clustered 
lysosomes 
3.11.1 Overexpression of DIRC2 in mammalian cells lead to the formation of enlarged and/or 
clustered of acidic compartments 
In an initial attempt to reveal a possible function of DIRC2, GFP-tagged constructs of 
DIRC2 were overexpressed in different cell-lines and analyzed by immunofluorescence. It 
was revealed that expression of C-terminally GFP-tagged DIRC2 (DIRC2-GFP, Figure 3.1) 
led to formation of enlarged or clustered acidic organelles in Cos7, HeLa and HEK293 cells, 
as detected by lysotracker (Figure 3.16, shown by arrow heads). Similar effect was also 
revealed by N-terminally GFP-tagged DIRC2 (GFP-DIRC2). This result underlines that 
enlargement or clustering of acidic organelles induced by overexpression of GFP-tagged 
DIRC2 does not depend on the position of the GFP tag. 
 
3.11.2 Effects of bafilomycin A1, vinblastine and Rab5 on the DIRC2-GFP driven 
enlargement of acidic organelles 
To investigate whether acidification of organelles is a prerequisite for the enlargement 
or clustering of organelles, Cos7 cells transfected with DIRC2 were treated with 20 nM 
bafilomycin A1, an inhibitor of vacuolar-type H
+
-ATPase (V-ATPase) (Droese and Altendorf 
1997). V-ATPase is the proton pump protein responsible for the proton transport into 
lysosomes and inhibition of V-ATPase prevents the acidification of lysosomes. It is shown in 
Figure 3.1.3 (A-F) that the formation of large organelles or cluster of organelles is apparently 
not affected by the administration of bafilomycin A1. Prolonged treatment with bafilomycin 
A1 up to more than 24 hours or increased concentration of bafilomycin up to 200 M did not 
change the enlarged vacuole formation (data not shown). This result suggests that lysosome 
acidification is not required for the vacuolation or organelle clustering. 
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Figure 3.2 Enlargement or clustering of acidic organelles upon overexpression of
GFP-tagged DIRC2 is independent of tag position
Figure to include: DIRC2-GFP (pEGFP.N1-DIRC2) and GFP-DIRC2 (pEGFP.C1-
DIRC2) overexpression in Cos7 cells
B Lysotracker
E LAMP-2 F Merge
C MergeA GFP
D GFP
 
 
 
 
 
 
 
 
 
 
Figure 3.16 Overexpression of DIRC2-GFP. 
Cos7, HeLa and HEK293 cells were transfected with DIRC2-GFP and fixed after 24 to 36 hours. Prior to 
fixation, cells were incubated with lysotracker (in plain DMEM). Distribution of DIRC2-GFP and acidic 
organelles as indicated by the accumulation of lysosomes was visualized by fluorescence microscopy. Figure A-
C, D-F and G-I show the overexpression of DIRC2-GFP in Cos7, HeLa and HEK293 cells, respectively. Arrow 
heads show the clustered organelles. Transfected cells are marked with asterisks.  Bars represent 10 m. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17 Large acidic organelle formations upon overexpression of GFP-DIRC2.  
Cos7 cells were transfected with N-terminally GFP-tagged DIRC2 (GFP-DIRC2, Figure 3.1 C). Cells were fixed 
two days after transfection. Acidic organelles were detected with lysotracker (B-C), and lysosomes were stained 
with anti-LAMP-2 followed by a fluorophore conjugated secondary antibody (E-F). Bars represent 10 m. 
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Figure 3.18 Effect of bafilomycin A1, vinblastine and Rab5 on the formation of large organelles.  
Cos7 cells were transfected with DIRC2-GFP. Acidic organelles were detected with lysotracker in the absence of 
bafilomysin A1 (A-C) or in the presence of 20 nM bafilomycin A (D-F).  Bafilomycin was added 3 hours prior 
to fixation. Depolymeration of tubulin is visualized by anti-tubulin antibody (K, L). G-I are untreated controls, 
whereas J-L are cells treated with 50 µM vinblastine 3 hours prior to fixation.  Effects of co-expression of 
DIRC2-GFP with the wild-type Rab5 and dominant negative form of Rab5 (Rab5S34N) are shown in M-R. Both 
wild-type Rab5 and Rab5S34N were detected by anti-Rab5 antibody followed by Alexa fluor 594 conjugated 
secondary antibody. Bars represent 10 m.  
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It has long been known that distribution or movement of lysosomes within a cell can 
be interfered by drugs or chemicals acting on microtubule or cell skeleton. One of these drugs 
is vinblastine, a chemotherapeutic agent used to treat numerous cancers, such as Hodgkin´s 
disease and testicular germ-cell cancer (Jordan and Wilson 2004). It acts by binding tubulin, 
thereby preventing the assembly of microtubules.  
In order to check whether the administration of vinblastine has an effect to the 
formation of enlarged or clustered organelles, DIRC2-GFP transfected Cos7 cells (Figure 3.1. 
C) were incubated with 50 µM vinblastine 3 hours prior to fixation. It is shown in the Figure 
3.18 that treatment of the cells with 50 µM vinblastine had no obvious effect on the 
vacuolation, indicating that the vacuolation and organelle cluster formation does not depend 
on the integrity of microtubules.   
Kuronita et al (Kuronita et al 2002) have reported that co-expression of LIMP-2 with 
the dominant negative form of small GTPase Rab5 can abolish the formation of large 
endosome/lysosomes compartment induced by overexpression of LIMP-2. It was emphasized 
that the GTP-bound form of Rab5 is important for the formation of large endosome/lysosome. 
Therefore, it was tested whether co-expression of the dominant negative form of Rab5 can 
also interfere with the formation of enlarged or clustered vacuoles induced by the 
overexpression of DIRC2. Figure 3.18 P-R shows that co-expression of DIRC2-GFP with 
Rab5S34N allowed the formation of cluster of organelles, similar to the result obtained by co-
expression of wild-type Rab5 (M-O), thus indicating that the formation of enlarged or 
clustered of organelles is independent of Rab5. 
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4. Discussion 
4.1 DIRC2 is a novel lysosomal protein  
 From its first report (Bodmer et al 2002), DIRC2 has readily been predicted from its 
sequence to be a member of the major facilitator superfamily. However, the cellular 
localization of DIRC2 was not resolved. In a further work by Schroeder (Schroeder et al 
2007), DIRC2 was identified as a putative member of lysosomal membrane proteins.  By 
using an indirect immunofluorescence and subcellular fractionation, it was demonstrated that 
DIRC2 is a lysosomal/late endosomal protein. This protein was shown to colocalize with 
lysosomal associated membrane protein type 2 (LAMP-2) and β-glucocerebrosidase (βGC), 
as well as with a late endosomal lipid lysobiphosphatidic acid (LBPA) in immunofluorescence 
analysis. In addition, DIRC2 was co-sedimenting with LAMP-2, βGC and cathepsin D in 
subcellular fractionation experiments. 
Like many other lysosomal membrane proteins, lysosomal targeting of DIRC2 was found 
to rely on a well known dileucine motif [DE]XXXL[LI] at its N-terminus. Two putative 
tyrosine-based lysosomal sorting motifs YXXØ are also identified at the C-terminus of 
DIRC2, but they were shown to be irrelevant for lysosomal targeting of DIRC2 (Dr. 
Schroeder, unpublished results). Most dileucine motifs of lysosomal proteins are located in 
close proximity (around 6 to 11 residues) to a transmembrane domain (Bonifacino and Traub 
2003). The short distance is thought to be important for the interaction between the dileucine 
signals with adaptor proteins (APs) which later forms complexes with clathrin. However, the 
dileucine motif in DIRC2 is 37 residues apart from the adjacent transmembrane segment. It is 
conceivable that interaction of the dileucine motif of DIRC2 with an AP complex is facilitated 
by a lipid modification. An example of this facilitation mechanism has been reported for 
mucolipin-1 which undergoes palmitoylation that promotes its endocytosis. Lipid 
modification exemplified here is thought to bring peptide sorting signals closer to the 
membrane (Vergarajauregui and Puertollano 2006, Braulke and Bonifacino 2009). Indeed, 
DIRC2 has a putative myristoylation modification site at Gly-2 which may help to activate the 
dileucine signal. However, experimental evidence is required to validate this presumption.  
 In a preliminary study, overexpression of GFP-tagged constructs of DIRC2 in different 
cell lines led to formation of enlarged and/or clustered lysosomes. These morphological 
alterations were shown to be independent of lysosomal acidification, integrity of microtubules 
or active form of Rab5. However, overexpression of DIRC2 with a triple myc tag showed no 
enlargement and/or clustering of lysosomes. It is likely that the formation of enlarged and/or 
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clustered lysosomes resulting from overexpression of GFP-DIRC2 constructs was mainly 
caused by the appended GFP tags, although the mechanism is not clear.          
  
4.2 DIRC2 is a glycoprotein 
DIRC2 was demonstrated to be a glycoprotein with N-glycosylation of Asn-209. It was 
also shown that DIRC2 acquires its core glycan moiety in the ER which is further processed 
in a post ER compartment. It has been reported in an N-glycosylation scanning study that 
arginine residues require a minimum distance of 12-14 residues to the membrane to be 
efficiently used for glycosylation or, in the context of polytopic membrane proteins, the loop 
segments must be longer than 30 residues in order to harbor N-glycans (Cheung and 
Reithmeier 2007). According to the predicted topology, the N-glycosylation site of DIRC2 
(Asn-209) is located in close proximity to the transmembrane segment in loop5 which is 
predicted to consist of only 16 residues. This may imply that the algorithm used to predict the 
protein topology may not precisely define the transmembrane and loop segments of DIRC2. It 
could also imply that the short glycosylation site distance to the closest transmembrane 
segment of DIRC2 is an exception from the general rule derived from the N-glycosylation 
scanning study described above. In comparison, a newer protein structure prediction software, 
I-TASSER (Zhang 2008; Roy et al 2010), would predict the N-glycosylation motif of DIRC2 
to be located in the middle region of its putative loop5 (Figure 4.1). However, the overall 
topology of DIRC2 described in this study is supported by the luminal residence of Asn-209 
as well as cytosolic localization of the dileucine targeting motif at the N- terminus (Figure 3.1 
B). 
 
 
Figure 4.1 Secondary structure prediction of DIRC2 generated by I-TASSER program. 
An alternative bioinformatics analysis of DIRC2 generated by I-TASSER program 
(http://zhanglab.ccmb.med.umich.edu/, Zhang 2008, Roy et al 2010) shows that the putative N-
glycosylation site Asn-209 is located approximately in the middle of two hydrophobic stretches 
corresponding to TM5 and TM6 of DIRC2. (Legends: C = coil, H = helix, S = scramble, Conf. Score = 
confidence score range from 0 to 9). 
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The unusual large carbohydrate moiety attached to Asn-209 of DIRC2 resembles that 
observed in the GLUT8 protein, a membrane protein of twelve transmembrane spanning 
domains. GLUT proteins are known to play a role in glucose/fructose transport across the 
membrane. Unlike its related proteins such as GLUT1-4 which were reported to localize in 
plasma membranes, GLUT8 was identified to localize in late endosomes/lysosomes. An 
apparent molecular weight shift of more than 10 kDa was reported upon PNGase digestion of 
GLUT8 which has only one N-linked glycosylation site in a loop between transmembrane 9 
and 10 (Augustin et al 2005). By the use of brefeldin A1, it could be shown DIRC2 acquires 
its core N-glycan in the ER and this glycan is further modified in a post-ER compartment.  
 
4.3 DIRC2 is proteolytically processed 
Lysosomes are known to be the degradation compartment of many macromolecules. This 
function is carried out by hydrolases within the lumen of lysosomes. Lysosomes are also the 
site for degradation of many plasma membrane proteins, including transporter proteins, after 
endocytic internalization (Schulze et al 2009). In this study, DIRC2 was shown to be 
proteolyzed in lysosomes. In the context described above, processing of DIRC2 in lysosomes 
may theoretically be regarded as the beginning of total degradation of DIRC2 proteins after 
serving their so far unknown function. However, since both overexpressed and endogenous 
DIRC2 showed an enormous stability in lysosomes, it seems likely that the observed 
processing of DIRC2 might represent a limited processing event rather than degradation. 
Moreover, the data in this study also revealed that endogenous DIRC2 was almost exclusively 
present in its proteolyzed form. 
Many examples of proteolytic events have recently been reported for numerous membrane 
proteins, including transporter proteins. Specific proteolytic cleavage of membrane proteins 
may negatively or positively modulate their functions. Glycine transporter 2 (GlyT2) for 
example, a member of of Na
+
/Cl
-
 -dependent plasma membrane transporters, which exhibits a 
cytoplasmic N-terminus that is at least three times longer than that of other members of 
neurotransmitter transporter family (Liu et al 1993), is cleaved by calpain proteases. The main 
cleavage site of this transporter protein is located in the N-terminal segment, and the 
remaining transmembrane fragment of the cleavage has a molecular weight of 70 kDa which 
is similar to other members of this protein family. The truncated GlyT2 displays full transport 
activity and it was suggested that the processing may contribute to the regulation of GlyT2 
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trafficking and/or function in the neuronal plasma membrane (Baliova et al 2004). Toll-like 
receptor 9 (TLR9), a pattern-recognition receptor localized in lysosomes/late endosomes, was 
reported to acquire its function and trigger signaling cascades activity in truncated form, 
although the full-length of TLR9 also exhibits significant activity. Cathepsin L and additional 
lysosomal proteases were suggested to be involved in the processing of TLR9 (Park et al 
2008).    
The current understanding of MFS proteins is deduced from high resolution structural data 
obtained for the lactose permease (LacY) (Abramson et al 2003) and the E. coli glycerol-3-
phosphate transporter (GlpT) (Huang et al 2003). Structural analysis of MFS proteins has 
revealed that the 12 transmembrane domains of MFS proteins are clustered into two halves of 
6 transmembrane-domains. The two clusters are pseudo-symmetric to each other with a pore 
between the two halves which is essential for substrate binding (Law et al 2008). In the case 
of LacY, it was demonstrated that the continuity of the polypeptide chain of the MFS protein 
is not essential for its activity. The two clusters of LacY can be expressed separately as non-
overlapping fragments and they are capable of reconstituting its transport activity comparable 
to the wild type protein (Weinglass and Kaback 2000). In addition, many studies have shown 
that the substrate binding site and the catalytic site of MFS proteins are largely determined by 
charged side chains of amino acid residues within transmembrane domains (reviewed by Law 
et al 2008). This may explain the persistent activity of discontinous clusters of LacY. Among 
MFS proteins, DIRC2 is the first protein reported to undergo proteolysis. While the function 
of DIRC2 is currently unknown, the need for (or the consequence of) DIRC2 proteolysis 
remains still illusive. Taken together, the enormous stability of proteolytic fragments of 
DIRC2 in lysosomes and the fact that MFS protein, as exemplified by LacY protein, may 
preserve it activity as discontinuous fragments, proteolytically processed DIRC2 may possess 
transport activity.  
 
 
4.4 Cathepsin L is involved in the processing of DIRC2 
In order to answer the question where the proteolysis of DIRC2 takes place and which 
protease(s) play(s) a role in the proteolysis of DIRC2, DIRC2 was overexpressed in HeLa 
cells in the presence or absence of different types of inhibitors. It is demonstrated that 
treatment of transfected HeLa cells with NH4Cl was able to prevent DIRC2 processing. 
NH4Cl is known to interfere with lysosomal acidification (Misinzo et al 2008). This result, 
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together with the data obtained from subcellular fractionation analysis, demonstrated that 
processing of DIRC2 is likely to take place in lysosomes. 
Inhibitory profiling of DIRC2 fragmentation with E-64, an inhibitor of cysteine 
proteases, revealed that DIRC2 is likely to be processed by this class of proteases. The 
possible involvement of cathepsin B and cathepsin L, two major lysosomal cysteine proteases, 
was investigated by addition of CA-074-Me and Z-FY-CHO, respectively, to HeLa cells 
transfected with DIRC2. It could be revealed that both cysteine protease inhibitors were able 
to prevent proteolysis of DIRC2. 
Historically, it has been commonly believed that lysosomal cathepsins may have 
common substrates. However, more recent findings indicated non-redundant functions of 
individual cathepsins (Roth et al 2000, Nagler and Menard 2003, Brix 2005). TRP-ML1, a 
lysosomal monovalent cation channel was reported to undergo proteolytic cleavage which 
was impaired by inhibition of cathepsin B (Kiselyov et al 2005). The pore-forming protein  
perforin precursor was reported to be activated by proteolytic cleavage, in part, by cathepsin L 
but not by cathepsin B (Konjar et al 2010). A further dissection of the role of cathepsin B and 
cathepsin L in the processing of DIRC2 was carried out by overexpressing human DIRC2 in 
cathepsin deficient MEFs. In contrast to the result described from the inhibitory profiling of 
DIRC2 processing, expression of DIRC2 in cathepsin deficient MEFs showed that cathepsin 
L, but not cathepsin B, is involved in the processing of DIRC2. This divergent observation is 
most likely due to an overlapping specificity of cathepsin B inhibitor CA-074-Me (Ebert et al 
2002, Montaser et al 2002). 
The sensitivity of DIRC2 to Z-FY-CHO treatment and the fact the DIRC2 is not 
proteolyzed in cathepsin L deficient MEF underlined the critical role of cathepsin L in the 
processing of DIRC2. However, it was revealed that only small amounts of DIRC2 remain 
unprocessed in livers of cathepsin L deficient mice. This result indicated that the role of 
cathepsin L in the processing of DIRC2 in mice liver is compensated by unknown proteases 
which are either absent or inactive in MEF cells. The fact that individual cathepsins contribute 
to certain functions in a tissue and cell type specific manner is highlighted by the proteolysis 
of invariant chain (li) which plays a role in the targeting of MHCII complexes in the thymus 
and antigen-presenting cells. In cathepsin L deficient mice, the role of cathepsin L in the 
processing of li in peripheral antigen-presenting cells such as dendritic cells, B-lymphocytes 
and macrophages is compensated by cathepsin S and cathepsin F which results in no 
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impairment of li processing in these cell types in cathepsin L deficient mice (Reinheckel et al 
2001).  
  
 
4.5 Cleavage site of DIRC2 
  To address the question where exactly DIRC2 is cleaved, several mutants of DIRC2 
were generated and expressed in HeLa cells. The fragmentation pattern of overexpressed wild 
type DIRC2 and the N209A mutant as well as the pattern of DIRC2 after PNGase F digestion 
indicated that DIRC2 is cleaved asymmetrically. Insertion of HA tags adjacent to residue 214 
and residue 261 within loop5 and loop6, respectively, more specifically showed that 
fragmentation of DIRC2 takes place between these two residues. Inhibitory profiling of the 
proteases involved in the processing of DIRC2 showed the important role of cathepsin L, a 
cysteine protease localized within the lumen of lysosomes.  
Together, the above described results narrowed down the likely cleavage site of 
DIRC2 within its loop5. According to the predicted DIRC2 topology, loop5 is limited by 
residues 210 to 229 connecting TM5 and TM6. As it would be expected for a cysteine 
protease, cathepsin L may cleave diverse peptide sequences. Nevertheless, a number of 
studies involving positional scanning synthetic combinatorial libraries (PS-SCL) of protease 
substrates have analyzed the preference cleavage sites of cathepsin L (examples are given in 
Table 4.1). 
One possible cleavage site within the loop5 by cathepsin L is the peptide bond 
between two alanine residues (-A216-A217-). Two leucine residues at the P2 and P3 positions 
are among the preferred target sites of cathepsin L (Choe et al 2006). However, mutation of 
amino acid at these positions with alanines in A1 mutant (A1: 211-TSPLLAAESS-220 → 211-
TAAAAAAESS-220; Figure 4.2) did not alter the processing of DIRC2. Oligopeptide sequence 
with an Arg at position P1` was reported to be a potential cleavage site for cathepsin L (Table 
4.1; Melo et al 2001).  Mutation of Arg-221 along with 3 amino acids at N-terminal of Arg-
221 in the A2 mutant (A2: 216-AAESSRAH-223 → 216-AAAAAAAAH-223; Figure 4.2) did also 
not prevent proteolysis of DIRC2. Both mutants are shown to be localized in lysosomes and 
processed by cathepsin L. 
Interestingly, substitution of a short luminal sequence directly bordering loop5 and 
TM6 with oligo-alanines resulted in a DIRC2 mutant (A3: 224-IKDRIEA-230 → 224-
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AAAAAAA-230; Figure 4.2) which is partially localized in ER and lysosomes. Oligopeptide 
sequence with Lys and Arg in the position P3 and P1, respectively, are preferable for 
cathepsin L cleavage. However, Asp and Glu at position P2 and P1´ are not favorable for 
cathepsin L digestion (Puzer et al 2004, Choe et al 2006). The fraction which reaches 
lysosomes is still processed in this compartment. In contrast, the fraction which is retained in 
the ER is not processed. An ER localization was also observed for the DIRC2 mutant where 
its TM6 sequence was replaced with a comparable TM6 sequence from an unrelated 
lysosomal MFS member CLN7 (data not shown). These results nevertheless underlined the 
critical role of amino acid residues bordering the TM6 for lysosomal localization or correct 
folding and membrane insertion of DIRC2.  
 
 
 
 
 
 
 
Table 4.1 Combinatorial substrate analyses of cathepsin L.   
Cleavage sequence preferences of human cathepsin L generated by positional scanning synthetic combinatorial 
libraries (PS-SCL) studies (adapted from http://merops.sanger.ac.uk/). Positions of amino acid residues are 
indicated by P4 to P1 and P1´to P4´ for amino acid residues at the N- and C-terminal from scissile sites and 
cleavages are taken place between P1 and P1´. 
 
Specificity from combinatorial peptides 
Optimal 
substrate 
Note/reference 
P4 P3 P2 P1 P1´ P2´ P3´ P4` 
- - - - R/A/K - - - XXXX/RXXX Melo et al 2001 
- K/R F R H/S S/H - - XKFR/HSXX Puzer et al 2004 
H/broad K/R/M/L F/W/Y R/K - - - - HKFR/XXXX Choe et al 2006 
 
 
 
 
Figure 4.2 Sequence of loop5 of DIRC2 and 
alanine scanning mutants. 
The sequence of loop5 of DIRC2 with 
predicted cleavages sites. Three alanine 
scanning mutation (A1, A2 and A3) used to 
analyse the cleavage site of DIRC2 are 
depicted.  
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4.6 Putative function of DIRC2 
Upon downregulation of DIRC2 with siRNAs in HeLa cells, no alterations in 
lysosomal enzyme activities or expression of lysosomal proteins was observed (Figure 3.8) 
was observed. In a collaborative work with Prof. Bruno Gasnier (CNRS Paris), it was 
suggested that DIRC2 may function as an electrogenic metabolite transporter. The 
experimental set-up led to this conclusion is described as follows: the dileucine mutant of 
DIRC2 was expressed in Xenopus oocytes which allows a plasma membrane expression of the 
full length form of DIRC2. Electrophysiological transport activity was detected by two-
electrode voltage clamp applied on the oocytes in an acidic medium (pH 5.0) which was 
supplemented with a metabolic mixture (Bacto Yeast Extract, BYE).  Application of this 
metabolic mixture induced a significant outward current. Since the extracellular medium is 
topologically equivalent to the lysosomal lumen in a whole cell set up, DIRC2 might facilitate 
transport of anions from lysosomes or exchange cations from the cytosol into lysosomes 
(Figure 4.3).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Putative role of DIRC2 as an electrogenic metabolite transporter. 
A possible transport function of DIRC2, as described in the text, was analyzed by expression of a dileucine 
mutant of DIRC at the plasma membrane of Xenopus oocytes. An equivalent situation in a whole cell where 
DIRC2 localizes to lysosomes is described in this figure. A three dimensional model of DIRC2, generated with I-
TASSER program, shows both N- and C-termini in the cytosolic environment and N-glycosylation site at the 
loop5 of DIRC2 within the lumen of lysosome. Cleavage site of DIRC2 by cathepsin L is presumably C-terminal 
from the glycosylation site. Outward current evoked by metabolites in the experiment with X. oocytes suggested 
an inward current from lysosomes. This may indicate that the substrates within the lysosomes are anions which 
counterbalance cations transport from the cytosol. 
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 The model described above with a current toward lysosomes or anions are being 
transported out of lysosomes is somehow surprising since lysosomal transporters are 
generally coupled with a proton efflux from lysosomes and counterbalanced with an outward 
current. Nevertheless, the possibility that anions efflux from lysosomes accounting for DIRC2 
activity is also supported by the fact that a high concentration of chloride ions was observed 
within lysosomes, as recently reported by Weinert and co-workers (Weinert et al 2010). It is 
also plausible that the DIRC2 operates as a symporter where the outward current from 
lysosomes is coupled with the efflux of catabolic products from lysosomes.  
 
4.7 Outlook 
It was shown in this study that DIRC2 is a lysosomal membrane protein. It is subject 
to proteolytic processing within the lysosomes which leads to fragmentation of DIRC2 into 
two asymmetric fragments. The cleavage site of DIRC2 is not yet clear. Scanning of amino 
acids in the loop5 which are adjacent to TM6 may reveal the exact cleavage site of DIRC2. 
Alternatively, the C-terminal fragment from overexpressed DIRC2-3xmyc can be purified by 
immunoaffinity chromatography and its N-terminal end representing the cleavage site by 
cathepsin L can be determined by Edman degradation of the amino terminus. 
Cathepsin L was shown to play a role in the processing of DIRC2. However, it is not 
clear whether cathepsin L directly cleaves DIRC2 or indirectly cleaves DIRC2 through 
activation of another protease(s). In vitro cleavage assay of DIRC2 with a recombinant 
cathepsin L was not successful (data not shown). Optimization of such an in vitro cleavage 
assay may be necessary by modifying both DIRC2 preparation and/or cleavage conditions.  
Upon successful in vitro cleavage assay, the DIRC2 fragments can be analyzed by MALDI-
TOF to determine the exact mass of each fragments from which the cleavage site of DIRC2 
can be deduced. 
Bioinformatic analysis of DIRC2 as well as results shown for the biochemical 
characterization of DIRC2 are in agreement that DIRC2 is a member of MFS proteins 
residing in the lysosomal membrane. However what function it plays in lysosomes is not 
clear. As current, there is no knock out mouse available to analyze the functional relevance of 
DIRC2 in vivo. Hence, preparation and analysis of such a DIRC2 knock out mouse is a 
promising strategy to identify the physiological role of DIRC2. 
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In an initial characterization of DIRC2 function by expression of a dileucine mutant of 
DIRC2 at the plasma membrane of Xenopus oocytes and testing its ability to take up 
metabolites, it was found that DIRC2 may act as an electrogenic transporter. It showed an 
outward current which counteracts influx of metabolites from the acidic, rich extracellular 
medium. This process is equivalent to efflux of catabolites from lysosomes and inward 
current into the lysosomes. By using the same approach, selective uptake of metabolites from 
the medium by DIRC2 expressed on the surface of Xenopus oocytes could be the method of 
choice to unravel the substrate of DIRC2.  
Upon identification of the substrate of full length form of DIRC2, it is of interest to 
analyze the influence of proteolytic processing on the function of DIRC2. A possible 
interaction between the DIRC2 fragments and the relevance its function could also provide 
valuable information in order to have a more comprehensive description of this transporter 
protein. 
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